notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
1_CD
Accounting_GER
policies_NN
Pension_NN
costs_VPRT
The_DT
costs_NN
of_PIN
the_DT
Groups_NN
defined_VBN
contribution_NOMZ
pension_NN
Accounting_GER
convention_NOMZ
and_PHC
presentation_NOMZ
arrangements_NOMZ
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
year_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
._.
The_DT
costs_NN
of_PIN
the_DT
Groups_NN
defined_VBN
cost_NN
convention_NOMZ
and_CC
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
benefits_NN
scheme_NN
are_VPRT [PASS]
charged_VBN
on_PIN
a_DT
systematic_JJ
basis_NN
allowing_VBG [SUAV] [WZPRES]
for_PIN
and_CC
applicable_JJ
UK_NN
accounting_GER
standards_NN
._.
The_DT
principal_JJ
accounting_GER
the_DT
expected_VBN [PRIV]
pension_NN
cost_NN
over_IN
the_DT
service_NN
lives_NN
of_PIN
employees_NN
,_,
policies_NN
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
consistently_RB
and_CC
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
The_DT
results_NN
for_PIN
the_DT
year_NN
all_QUAN
relate_VPRT
to_TO
continuing_VBG
operations_NOMZ
._.
The_DT
financial_JJ
statements_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
on_PIN
a_DT
going_VBG
concern_NN
basis_NN
._.
Employee_NN
share_NN
plans_VPRT
Incentives_NN
in_PIN
the_DT
form_NN
of_PIN
shares_NN
are_VPRT [PASS]
provided_VBN
to_PIN
employees_NN
under_IN
Consolidation_NOMZ
share_NN
option_NOMZ
and_PHC
share_NN
award_NN
schemes_NN
._.
In_PIN
respect_NN
of_PIN
award_NN
The_DT
consolidated_JJ
financial_JJ
information_NOMZ
includes_VPRT
the_DT
financial_JJ
schemes_NN
the_DT
Group_NN
provides_VPRT
finance_NN
to_PIN
an_DT
employee_NN
share_NN
statements_NOMZ
for_PIN
the_DT
Company_NN
and_CC
its_PIT
subsidiary_NN
undertakings_GER
._.
ownership_NN
trust_NN
to_TO
purchase_VB
company_NN
shares_NN
on_PIN
the_DT
open_JJ
Intra-Group_NN
sales_NN
and_PHC
profits_NN
are_VPRT [PASS]
eliminated_VBN
fully_AMP
on_PIN
market_NN
to_TO
meet_VB
the_DT
Groups_NN
obligation_NOMZ
to_TO
provide_VB
shares_NN
when_RB
consolidation_NOMZ
._.
The_DT
results_NN
of_PIN
subsidiaries_NN
sold_VBN
or_CC
acquired_VBN
are_VPRT
employees_NN
exercise_VPRT
their_TPP3
award_NN
._.
The_DT
difference_NN
between_PIN
the_DT
included_VBN
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_VPRT
up_RP
to_PIN
the_DT
purchase_NN
price_NN
of_PIN
the_DT
shares_NN
and_CC
the_DT
exercise_NN
price_NN
of_PIN
the_DT
award_NN
date_NN
of_PIN
their_TPP3
sale_NN
or_CC
from_PIN
their_TPP3
date_NN
of_PIN
acquisition_NOMZ
respectively_RB
._.
is_VPRT [PASS]
charged_VBN
,_,
or_CC
credited_VBN
,_,
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
over_IN
the_DT
periods_NN
of_PIN
service_NN
in_PIN
respect_NN
of_PIN
which_WDT [PIRE]
the_DT
award_NN
was_VBD [PASS]
granted_VBN [SUAV]
._.
Revenue_NN
recognition_NOMZ
Turnover_NN
comprises_VPRT
contract_NN
development_NOMZ
and_PHC
licensing_GER
,_,
royalty_NN
The_DT
costs_NN
of_PIN
running_VBG
the_DT
employee_NN
share_NN
ownership_NN
trust_NN
are_VPRT
and_CC
manufacturing_GER
and_PHC
distribution_NOMZ
income_NN
._.
Contract_NN
charged_VBD
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
accrue_VPRT
._.
development_NOMZ
and_PHC
licensing_GER
income_NN
represents_VPRT
amounts_NN
invoiced_VBD
to_PIN
customers_NN
for_PIN
services_NN
rendered_VBN
under_IN
development_NOMZ
and_PHC
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
employee_NN
share_NN
ownership_NN
trust_NN
are_VPRT
licensing_VBG
agreements_NOMZ
,_,
including_VBG
milestone_NN
payments_NOMZ
and_CC
accounted_VBD
for_PIN
as_IN
fixed_JJ
asset_NN
investments_NOMZ
at_PIN
cost_NN
less_JJ
accrual_NN
for_PIN
technology_NN
access_NN
fees_NN
._.
Contract_NN
revenue_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
when_RB [WHCL]
costs_NN
charged_VBN
._.
earned_VBN
and_CC
non-refundable_JJ
and_CC
to_PIN
the_DT
extent_NN
that_DEMO
there_EX
are_VPRT
no_SYNE
future_JJ
obligations_NOMZ
pursuant_JJ
to_PIN
the_DT
revenue_NN
,_,
in_PIN
accordance_NN
with_PIN
Intangible_JJ
fixed_JJ
assets_NN
the_DT
contract_NN
terms_NN
._.
Refundable_JJ
contract_NN
revenue_NN
is_VPRT [PASS]
treated_VBN
as_IN
Intangible_JJ
fixed_JJ
assets_NN
comprise_VPRT
goodwill_NN
,_,
intellectual_JJ
property_NN
deferred_VBN
until_IN
such_JJ
time_NN
as_IN
it_PIT
is_VPRT
no_RB
longer_RB
refundable_JJ
._.
Royalty_NN
and_CC
capitalized_JJ
development_NOMZ
costs_NN
._.
Goodwill_NN
,_,
being_VBG [PRESP] [BEMA]
the_DT
income_NN
represents_VPRT
income_NN
earned_VBD
as_IN
a_DT
percentage_NN
of_PIN
product_NN
difference_NN
between_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
purchase_NN
consideration_NOMZ
sales_NN
._.
Advance_NN
royalties_NN
received_VBD
are_VPRT [PASS]
treated_VBN
as_IN
deferred_JJ
income_NN
and_CC
the_DT
Groups_NN
share_NN
of_PIN
the_DT
fair_JJ
value_NN
of_PIN
the_DT
net_JJ
assets_NN
acquired_VBN
,_,
until_IN
earned_VBN
,_,
when_RB
they_TPP3
are_VPRT [PASS]
recognized_VBN [PRIV]
as_IN
income_NN
._.
is_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
a_DT
period_NN
of_PIN
20_CD
years_NN
or_CC
less_JJ
in_PIN
Manufacturing_GER
and_PHC
distribution_NOMZ
revenues_NN
principally_RB
comprise_VPRT
line_NN
with_PIN
the_DT
Directors_NN
view_NN
of_PIN
its_PIT
useful_JJ
economic_JJ
life_NN
._.
Prior_RB
to_PIN
contract_NN
manufacturing_GER
fees_NN
invoiced_VBD
to_PIN
third_JJ
parties_NN
and_PHC
income_NN
the_DT
introduction_NOMZ
of_PIN
FRS_NN
10_CD
:_:
Goodwill_NN
and_CC
intangible_JJ
assets_NN
,_,
the_DT
from_PIN
product_NN
sales_NN
._.
policy_NN
adopted_VBN [WZPAST]
was_VBD
to_TO
write_VB [PUBV]
off_PIN
goodwill_NN
to_PIN
reserves_NN
._.
As_IN
permitted_VBN
by_PIN
FRS_NN
10_CD
goodwill_NN
written_VBN [PUBV] [WZPAST]
off_PIN
to_PIN
reserves_NN
in_PIN
previous_JJ
years_NN
has_VPRT
Research_NN
and_PHC
development_NOMZ
costs_NN
not_XX0
been_VBN [PASS]
reinstated_VBN
on_PIN
the_DT
balance_NN
sheet_NN
and_PHC
adjustments_NOMZ
to_PIN
Research_NN
and_PHC
development_NOMZ
costs_NN
are_VPRT [PASS]
charged_VBN
as_IN
an_DT
expense_NN
in_PIN
such_JJ
goodwill_NN
have_VPRT [PEAS]
been_VBN [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
._.
Goodwill_NN
the_DT
period_NN
in_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
incurred_VBN
._.
previously_TIME
written_VBN [PUBV]
off_PIN
to_PIN
reserves_NN
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
event_NN
of_PIN
disposal_NN
of_PIN
the_DT
related_JJ
business_NOMZ
._.
Foreign_JJ
currency_NN
transactions_NOMZ
Foreign_JJ
currency_NN
transactions_NOMZ
by_PIN
Group_NN
companies_NN
are_VPRT [PASS]
recorded_VBN
Intellectual_NN
property_NN
comprises_VPRT
acquired_VBN
patents_NN
,_,
trade_NN
marks_NN
,_,
in_PIN
local_JJ
currency_NN
at_PIN
the_DT
exchange_NN
rate_NN
ruling_NN
on_PIN
the_DT
date_NN
of_PIN
know-how_NN
and_CC
other_JJ
similarly_CONJ
identified_VBN
rights_NN
._.
Assets_NN
and_PHC
liabilities_NOMZ
expressed_VBN [WZPAST]
in_PIN
foreign_JJ
recorded_VBN
at_PIN
their_TPP3
fair_JJ
value_NN
at_PIN
acquisition_NOMZ
date_NN
and_CC
are_VPRT [PASS]
amortised_VBN
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
sterling_GER
at_PIN
the_DT
exchange_NN
rates_NN
in_PIN
equal_JJ
instalments_NOMZ
over_IN
their_TPP3
estimated_VBN [PRIV]
useful_JJ
economic_JJ
lives_NN
,_,
ruling_VBG [SUAV] [PRESP]
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
._.
Exchange_NN
differences_NN
which_WDT [WHOBJ]
from_PIN
the_DT
date_NN
when_RB
the_DT
transfer_NN
of_PIN
technology_NN
is_VPRT [BEMA]
complete_PRED
._.
The_DT
relate_VPRT
to_PIN
the_DT
retranslation_NOMZ
of_PIN
net_JJ
assets_NN
of_PIN
overseas_PLACE
companies_NN
period_NN
over_IN
which_WDT
the_DT
Group_NN
expects_VPRT [PRIV]
to_TO
derive_VB
economic_JJ
benefits_NN
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
._.
All_QUAN
other_JJ
foreign_JJ
exchange_NN
does_VPRT
not_XX0
exceed_VB
20_CD
years_NN
._.
Costs_NN
associated_VBN [WZPAST]
with_PIN
internally_RB
differences_NN
are_VPRT [PASS]
taken_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
year_NN
in_PIN
developed_JJ
intellectual_JJ
property_NN
are_VPRT [SPAU] [PASS]
generally_RB
treated_VBN
as_IN
research_NN
which_WDT [WHOBJ]
they_TPP3
arise_VPRT
._.
The_DT
Group_NN
uses_VPRT
the_DT
average_JJ
exchange_NN
rates_NN
and_PHC
development_NOMZ
costs_NN
._.
prevailing_VBG [PRESP]
during_PIN
the_DT
year_NN
to_TO
translate_VB
the_DT
results_NN
of_PIN
overseas_PLACE
subsidiaries_NN
into_PIN
sterling_GER
and_PHC
year-end_NN
rates_NN
to_TO
translate_VB
the_DT
net_JJ
assets_NN
of_PIN
those_DEMO
undertakings_GER
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
58_CD
59_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
1_CD
Accounting_GER
policies_NN
continued_VBD
Convertible_JJ
debt_NN
On_PIN
issue_NN
,_,
convertible_JJ
debt_NN
is_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
amount_NN
of_PIN
net_JJ
Tangible_JJ
fixed_JJ
assets_NN
proceeds_NN
after_IN
deducting_VBG
issue_NN
costs_NN
._.
On_PIN
conversion_NN
,_,
the_DT
amount_NN
Tangible_JJ
fixed_JJ
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
cost_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
shareholders_NN
funds_NN
in_PIN
respect_NN
of_PIN
the_DT
shares_NN
less_RB
accumulated_VBN
depreciation_NOMZ
._.
Depreciation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
issued_VBN
is_VPRT [BEMA]
equal_PRED
to_PIN
the_DT
carrying_VBG
value_NN
at_PIN
the_DT
date_NN
of_PIN
conversion_NN
._.
tangible_JJ
fixed_JJ
assets_NN
at_PIN
rates_NN
calculated_VBN [PRIV]
to_TO
write_VB [PUBV]
off_PIN
the_DT
cost_NN
,_,
less_JJ
Interest_NN
payable_JJ
on_PIN
convertible_JJ
debt_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
to_TO
unwind_VB
the_DT
estimated_VBN [PRIV]
residual_JJ
value_NN
,_,
of_PIN
each_QUAN
asset_NN
over_IN
its_PIT
expected_VBN [PRIV]
useful_JJ
issue_NN
costs_NN
and_CC
any_QUAN
discount_NN
on_PIN
issue_NN
at_PIN
a_DT
constant_JJ
rate_NN
over_IN
the_DT
life_NN
._.
The_DT
rates_NN
and_PHC
bases_NN
are_VPRT
as_IN
follows_VPRT
:_:
term_NN
of_PIN
the_DT
debt_NN
._.
Freehold_NN
land_NN
not_XX0
depreciated_VBD
Deferred_JJ
consideration_NOMZ
Freehold_NN
buildings_GER
2_CD
%_NN
5_CD
%_NN
straight_JJ
line_NN
Provisions_NN
for_PIN
deferred_JJ
consideration_NOMZ
comprise_VPRT
the_DT
fair_JJ
value_NN
of_PIN
Short_JJ
leasehold_NN
property_NN
period_NN
of_PIN
lease_NN
contingent_JJ
consideration_NOMZ
arising_VBG [WZPRES]
from_PIN
acquisitions_NOMZ
._.
The_DT
eventual_JJ
Plant_NN
,_,
equipment_NOMZ
and_PHC
fixtures_NN
10_CD
%_NN
33_CD
%_NN
straight_JJ
line_NN
outcome_NN
is_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
Groups_NN
future_JJ
performance_NN
and_PHC
Motor_NN
vehicles_NN
20_CD
%_NN
straight_JJ
line_NN
certain_JJ
contractual_JJ
terms_NN
._.
Provisions_NN
are_VPRT [PASS]
reviewed_VBN
annually_RB
by_PIN
Finance_NN
leases_VPRT
period_NN
of_PIN
lease_NN
the_DT
Directors_NN
,_,
and_ANDC
changes_NN
to_PIN
the_DT
estimated_VBN [PRIV]
fair_JJ
value_NN
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
are_VPRT [PASS]
recorded_VBN
as_IN
an_DT
adjustment_NOMZ
to_PIN
Fixed_JJ
asset_NN
investments_NOMZ
goodwill_NN
or_CC
the_DT
underlying_JJ
asset_NN
value_NN
._.
Investments_NOMZ
that_TSUB
are_VPRT [PASS]
held_VBN [PRIV]
for_PIN
continuing_VBG
use_NN
in_PIN
the_DT
business_NOMZ
are_VPRT [PASS]
classified_VBN
as_IN
fixed_JJ
asset_NN
investments_NOMZ
and_CC
recorded_VBN
in_PIN
the_DT
balance_NN
Deferred_VBN
taxation_NOMZ
sheet_NN
at_PIN
cost_NN
or_CC
Directors_NN
valuation_NOMZ
,_,
less_JJ
provision_NN
for_PIN
Deferred_JJ
taxation_NOMZ
is_VPRT [PASS]
provided_VBN
on_PIN
timing_NN
differences_NN
which_WDT [WHOBJ]
at_PIN
the_DT
permanent_JJ
diminution_NOMZ
in_PIN
value_NN
._.
balance_NN
sheet_NN
date_NN
result_NN
in_PIN
an_DT
obligation_NOMZ
to_TO
pay_VB
more_EMPH
tax_NN
or_CC
a_DT
right_NN
to_TO
pay_VB
less_JJ
tax_NN
at_PIN
a_DT
future_JJ
date_NN
,_,
at_PIN
rates_NN
expected_VBN [PRIV]
to_TO
apply_VB
Impairment_NOMZ
of_PIN
fixed_JJ
assets_NN
when_RB
they_TPP3
crystallise_VPRT
based_VBN
on_PIN
current_JJ
tax_NN
rates_NN
and_PHC
law_NN
._.
The_DT
carrying_VBG
values_NN
of_PIN
fixed_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
Deferred_VBN
tax_NN
assets_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
to_PIN
the_DT
extent_NN
that_TOBJ
it_PIT
is_VPRT
when_RB
there_EX
is_VPRT
an_DT
indication_NOMZ
that_TOBJ
the_DT
assets_NN
may_POMD
be_VB [PASS]
impaired_VBN
._.
regarded_VBN
as_IN
more_EMPH
likely_JJ
than_PIN
not_XX0
that_DEMO
they_TPP3
will_PRMD
be_VB [PASS]
recovered_VBN
._.
First_JJ
year_NN
impairment_NOMZ
reviews_NN
are_VPRT [PASS]
conducted_VBN
for_PIN
acquired_VBN
Deferred_JJ
tax_NN
assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
Impairment_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
higher_JJ
of_PIN
net_JJ
realisable_JJ
value_NN
and_PHC
value_NN
in_PIN
use_NN
,_,
Financial_NN
instruments_NOMZ
which_WDT [WHSUB]
is_VPRT [BYPA]
measured_VBN
by_PIN
reference_NN
to_PIN
discounted_JJ
future_JJ
cash_NN
flows_NN
._.
The_DT
Group_NN
uses_VPRT
derivative_JJ
financial_JJ
instruments_NOMZ
to_TO
hedge_VB
its_PIT
Any_QUAN
provision_NN
for_PIN
impairment_NOMZ
is_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
exposure_NN
to_PIN
fluctuations_NOMZ
in_PIN
interest_NN
and_CC
foreign_JJ
exchange_NN
rates_NN
._.
account_NN
in_PIN
the_DT
year_NN
concerned_VBN
._.
Specifically_RB
,_,
the_DT
Group_NN
uses_VPRT
interest_NN
rate_NN
swaps_NN
,_,
forward_RB
currency_NN
contracts_NN
and_PHC
currency_NN
options_NOMZ
._.
Receipts_NN
and_PHC
Stock_NN
and_CC
work-in-progress_JJ
payments_NOMZ
on_PIN
interest_NN
rate_NN
swaps_NN
are_VPRT [PASS]
recognized_VBN [PRIV]
on_PIN
an_DT
accruals_NN
Stock_NN
and_PHC
work-in-progress_NN
are_VPRT [PASS]
valued_VBN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_PHC
basis_NN
,_,
over_IN
the_DT
life_NN
of_PIN
the_DT
swap_NN
,_,
as_IN
an_DT
adjustment_NOMZ
to_PIN
interest_NN
net_NN
realisable_JJ
value_NN
and_CC
calculated_VBN [PRIV]
using_VBG
the_DT
first-in_PIN [STPR]
,_,
first-out_PIN
payable_JJ
._.
Gains_NN
and_PHC
losses_NN
on_PIN
forward_JJ
currency_NN
contracts_NN
and_PHC
basis_NN
._.
currency_NN
options_NOMZ
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
the_DT
period_NN
that_TOBJ
the_DT
foreign_JJ
currency_NN
exposure_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
._.
Option_NOMZ
premia_NN
are_VPRT [BEMA]
Current_JJ
asset_NN
investments_NOMZ
deferred_VBN [WZPAST]
in_PIN
the_DT
balance_NN
sheet_NN
and_CC
recognized_VBN [PRIV]
upon_PIN
the_DT
maturity_NOMZ
Investments_NOMZ
held_VBD [PRIV]
other_JJ
than_PIN
for_PIN
continuing_VBG
use_NN
in_PIN
the_DT
business_NOMZ
of_PIN
the_DT
option_NOMZ
agreement_NOMZ
._.
are_VPRT [PASS]
classified_VBN
as_IN
current_JJ
asset_NN
investments_NOMZ
and_CC
recorded_VBN
in_PIN
the_DT
balance_NN
sheet_NN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
._.
Future_JJ
requirements_NOMZ
In_PIN
December_NN
2003_CD
the_DT
Urgent_NN
Issues_NN
Task_NN
Force_NN
issued_VBD
Abstract_NN
Liquid_NN
resources_NN
38_CD
:_:
Accounting_GER
for_PIN
ESOP_NN
trusts_NN
and_CC
amended_VBN
Abstract_NN
17_CD
:_:
Liquid_NN
resources_NN
comprise_VPRT
short-term_JJ
bank_NN
and_CC
commercial_JJ
Employee_NN
share_NN
schemes_NN
relating_VBG [WZPRES]
to_PIN
employee_NN
share_NN
ownership_NN
deposits_NN
with_PIN
a_DT
maturity_NOMZ
of_PIN
less_JJ
than_PIN
one_CD
year_NN
._.
These_DEMO
requirements_NOMZ
are_VPRT [BEMA]
effective_PRED
for_PIN
accounting_GER
periods_NN
ending_VBG [WZPRES]
on_PIN
or_CC
after_IN
22_CD
June_NN
2004_CD
and_CC
will_PRMD
require_VB [SUAV]
the_DT
Leased_NN
and_CC
hired_VBD
assets_NN
shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
ESOT_NN
to_TO
be_VB [PASS]
shown_VBN [PRIV]
as_IN
a_DT
deduction_NOMZ
from_PIN
Leasing_GER
agreements_NOMZ
which_WDT [WHSUB]
transfer_VPRT
to_PIN
the_DT
Group_NN
substantially_RB
shareholders_NN
funds_NN
._.
The_DT
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_VPRT
all_QUAN
of_PIN
the_DT
risks_NN
and_PHC
rewards_NN
of_PIN
ownership_NN
of_PIN
an_DT
asset_NN
are_VPRT [PASS]
treated_VBN
will_PRMD
be_VB [BEMA]
the_DT
difference_NN
between_PIN
the_DT
market_NN
price_NN
and_CC
the_DT
exercise_NN
as_IN
finance_NN
leases_NN
._.
The_DT
assets_NN
are_VPRT [PASS]
included_VBN
in_PIN
tangible_JJ
fixed_VBN
price_NN
at_PIN
date_NN
of_PIN
grant_NN
._.
assets_NN
and_CC
the_DT
capital_NN
element_NOMZ
of_PIN
amounts_NN
owed_VBN [WZPAST]
to_PIN
the_DT
finance_NN
company_NN
at_PIN
the_DT
balance_NN
sheet_NN
date_NN
is_VPRT [PASS]
included_VBN
in_PIN
creditors_NN
as_IN
In_PIN
June_NN
2002_CD
,_,
the_DT
Council_NN
of_PIN
the_DT
European_NN
Union_NN
adopted_VBD
a_DT
amounts_NN
falling_VBG [WZPRES]
due_JJ
either_CC
within_PIN
or_CC
after_IN
more_EMPH
than_PIN
one_CD
year_NN
._.
Regulation_NOMZ
requiring_VBG [SUAV] [WZPRES]
listed_VBN
companies_NN
in_PIN
its_PIT
Member_NN
States_NN
Repayments_NOMZ
are_VPRT [PASS]
treated_VBN
as_IN
consisting_VBG
of_PIN
both_DT
capital_NN
and_CC
to_TO
prepare_VB
consolidated_JJ
financial_JJ
statements_NOMZ
in_PIN
accordance_NN
interest_NN
with_PIN
the_DT
interest_NN
element_NOMZ
being_VBG [WZPRES] [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_CC
with_PIN
International_NN
Financial_NN
Reporting_GER
Standards_NN
IFRS_NN
from_PIN
loss_NN
account_NN
in_PIN
proportion_NOMZ
to_PIN
the_DT
outstanding_JJ
obligations_NOMZ
._.
The_DT
first_JJ
SkyePharma_NN
Annual_JJ
Report_NN
prepared_VBD
Payments_NOMZ
under_IN
operating_VBG
leases_NN
and_CC
short-term_JJ
hire_NN
contracts_NN
under_IN
IFRS_NN
will_PRMD
be_VB [BEMA]
for_PIN
the_DT
year_NN
ending_VBG [WZPRES]
31_CD
December_NN
2005_CD
._.
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
they_TPP3
fall_VPRT
due_JJ
._.
The_DT
Group_NN
has_VPRT [PEAS]
commenced_VBN
a_DT
project_NN
to_TO
convert_VB
its_PIT
principal_JJ
financial_JJ
reporting_GER
from_PIN
UK_NN
GAAP_NN
to_PIN
IFRS_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
2_CD
Segmental_JJ
analysis_NN
The_DT
Groups_NN
operations_NOMZ
relate_VPRT
wholly_RB
to_PIN
one_CD
class_NN
of_PIN
business_NOMZ
,_,
pharmaceuticals_NN
._.
Further_JJ
analysis_NN
of_PIN
turnover_NN
,_,
loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
and_CC
net_JJ
assets_NN
by_PIN
geographical_JJ
area_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
,_,
together_RB
with_PIN
an_DT
analysis_NN
of_PIN
cost_NN
of_PIN
sales_NN
._.
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
a_DT
Turnover_NN
By_PIN
class_NN
of_PIN
business_NOMZ
:_:
Pharmaceuticals_NN
Contract_NN
development_NOMZ
and_PHC
licensing_GER
Milestone_NN
payments_NOMZ
24,196_CD
47,736_CD
Research_NN
and_PHC
development_NOMZ
costs_NN
recharged_VBD
5,456_CD
7,705_CD
29,652_CD
55,441_CD
Royalties_NN
receivable_JJ
18,701_CD
6,751_CD
Manufacturing_GER
and_PHC
distribution_NOMZ
4,799_CD
7,381_CD
53,152_CD
69,573_CD
By_PIN
location_NOMZ
of_PIN
customer_NN
:_:
UK_NN
21,327_CD
21,000_CD
Europe_NN
18,027_CD
10,333_CD
North_NN
America_NN
10,289_CD
34,047_CD
Rest_VPRT
of_PIN
the_DT
world_NN
3,509_CD
4,193_CD
53,152_CD
69,573_CD
By_PIN
location_NOMZ
of_PIN
operation_NOMZ
:_:
Europe_NN
42,503_CD
34,449_CD
North_NN
America_NN
10,649_CD
35,124_CD
53,152_CD
69,573_CD
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
b_NN
Cost_NN
of_PIN
sales_NN
By_PIN
class_NN
of_PIN
business_NOMZ
:_:
Pharmaceuticals_NN
Contract_NN
development_NOMZ
and_PHC
licensing_GER
12,085_CD
12,649_CD
Royalties_NN
payable_JJ
4,707_CD
1,374_CD
Manufacturing_GER
and_PHC
distribution_NOMZ
12,994_CD
10,807_CD
29,786_CD
24,830_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
60_CD
61_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
2_CD
Segmental_JJ
analysis_NN
continued_VBD
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
c_NN
Loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
By_PIN
class_NN
of_PIN
business_NOMZ
:_:
Pharmaceuticals_NN
42,983_CD
1,333_CD
By_PIN
location_NOMZ
of_PIN
operation_NOMZ
:_:
UK_NN
5,825_CD
7,695_CD
Europe_NN
3,424_CD
7,652_CD
North_NN
America_NN
30,270_CD
4,759_CD
Operating_GER
loss_NN
profit_NN
39,519_CD
4,716_CD
Net_JJ
interest_NN
payable_JJ
3,464_CD
3,383_CD
Loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
42,983_CD
1,333_CD
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
d_SYM
Net_JJ
assets_NN
By_PIN
class_NN
of_PIN
business_NOMZ
:_:
Pharmaceuticals_NN
86,265_CD
124,270_CD
By_PIN
location_NOMZ
of_PIN
operation_NOMZ
:_:
UK_NN
145,727_CD
151,673_CD
Europe_NN
70,739_CD
69,489_CD
North_NN
America_NN
11,277_CD
42,086_CD
86,265_CD
124,270_CD
3_CD
Other_JJ
operating_GER
income_NN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
provided_VBD
a_DT
total_NN
of_PIN
$_$
30_CD
million_CD
between_PIN
2000_CD
and_CC
2002_CD
,_,
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
portion_NOMZ
of_PIN
the_DT
potential_JJ
future_NN
royalty_NN
and_PHC
revenue_NN
streams_NN
from_PIN
DepoMorphine_NN
,_,
Xatral_NN
OD_NN
,_,
Solaraze_NN
and_PHC
DepoCyt_NN
._.
Paul_NN
Capital_NN
will_PRMD
receive_VB
15_CD
%_NN
of_PIN
the_DT
annual_JJ
royalties_NN
and_PHC
revenues_NN
from_PIN
the_DT
stated_VBN [PUBV]
products_NN
up_IN
to_PIN
a_DT
predetermined_VBN
ceiling_GER
for_PIN
the_DT
period_NN
until_IN
31_CD
December_NN
2014_CD
._.
Once_TIME
the_DT
predetermined_VBN
ceiling_GER
is_VPRT [PASS]
reached_VBN
,_,
the_DT
percentage_NN
participation_NOMZ
will_PRMD
fall_VB
to_PIN
3_CD
%_NN
for_PIN
the_DT
remainder_NN
of_PIN
the_DT
period_NN
until_IN
31_CD
December_NN
2014_CD
._.
Income_NN
of_PIN
1.1_CD
million_CD
2002_CD
:_:
9.7_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
as_IN
Other_JJ
operating_GER
income_NN
under_IN
this_DEMO
agreement_NOMZ
on_PIN
a_DT
cost_NN
to_TO
complete_VB
basis_NN
._.
All_QUAN
of_PIN
the_DT
income_NN
under_IN
this_DEMO
agreement_NOMZ
has_VPRT [SPAU] [PEAS]
now_TIME
been_VBN [PASS]
recognized_VBN [PRIV]
._.
Royalty_NN
payments_NOMZ
to_PIN
Paul_NN
Capital_NN
of_PIN
1.0_CD
million_CD
2002_CD
:_:
Nil_NN
have_VPRT [PEAS]
been_VBN [PASS]
expensed_VBN
during_PIN
the_DT
year_NN
._.
Under_IN
a_DT
second_JJ
transaction_NOMZ
Paul_NN
Capital_NN
provided_VBD
a_DT
further_JJ
$_$
30_CD
million_CD
during_PIN
2002_CD
and_CC
2003_CD
,_,
in_PIN
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
portion_NOMZ
of_PIN
the_DT
potential_JJ
future_NN
royalty_NN
and_PHC
revenue_NN
streams_NN
from_PIN
nine_CD
products_NN
from_PIN
the_DT
Groups_NN
drug_NN
pipeline_NN
._.
Paul_NN
Capital_NN
will_PRMD
receive_VB
between_PIN
4_CD
%_NN
and_CC
20_CD
%_NN
of_PIN
the_DT
annual_JJ
royalties_NN
and_PHC
revenues_NN
from_PIN
the_DT
nine_CD
products_NN
up_IN
to_PIN
a_DT
predetermined_VBN
ceiling_GER
for_PIN
the_DT
period_NN
until_IN
31_CD
December_NN
2015_CD
._.
The_DT
20_CD
%_NN
rate_NN
applies_VPRT
first_RB
and_CC
the_DT
percentage_NN
then_RB
falls_VPRT
,_,
when_RB
an_DT
agreed_VBN [SUAV] [PUBV] [THATD]
ceiling_GER
is_VPRT [PASS]
reached_VBN
,_,
to_PIN
12.5_CD
%_NN
until_IN
a_DT
second_JJ
ceiling_GER
is_VPRT [PASS]
reached_VBN
,_,
before_IN
falling_VBG
to_PIN
4_CD
%_NN
for_PIN
the_DT
remainder_NN
of_PIN
the_DT
period_NN
until_IN
31_CD
December_NN
2015_CD
._.
During_PIN
2002_CD
and_CC
2003_CD
the_DT
20_CD
%_NN
rate_NN
was_VBD [PASS]
reduced_VBN
based_VBN
on_PIN
the_DT
percentage_NN
of_PIN
the_DT
total_JJ
$_$
30_CD
million_CD
that_DEMP
had_VBD [PEAS]
been_VBN [PASS]
provided_VBN
._.
Income_NN
of_PIN
5.0_CD
million_CD
2002_CD
:_:
4.5_CD
million_CD
was_VBD [PASS]
recognized_VBN [PRIV]
as_IN
Other_JJ
operating_GER
income_NN
under_IN
this_DEMO
agreement_NOMZ
on_PIN
a_DT
cost_NN
to_TO
complete_VB
basis_NN
._.
Royalty_NN
payments_NOMZ
to_PIN
Paul_NN
Capital_NN
of_PIN
2.2_CD
million_CD
2002_CD
:_:
0.7_CD
million_CD
have_VPRT [PEAS]
been_VBN [PASS]
expensed_VBN
during_PIN
the_DT
year_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
4_CD
Exceptional_JJ
items_NN
The_DT
operating_GER
exceptional_JJ
items_NN
included_VBD
within_PIN
administration_NOMZ
expenses_NN
are_VPRT [PASS]
categorised_VBN
as_IN
follows_VPRT
:_:
000_CD
Restructuring_GER
costs_NN
2,673_CD
Impairment_NOMZ
of_PIN
intellectual_JJ
property_NN
2,673_CD
Impairment_NOMZ
of_PIN
tangible_JJ
fixed_JJ
assets_NN
1,324_CD
Write_VB [PUBV]
down_IN
of_PIN
fixed_JJ
asset_NN
investments_NOMZ
1,599_CD
Settlement_NOMZ
of_PIN
licensing_GER
dispute_NN
1,218_CD
9,487_CD
The_DT
exceptional_JJ
charge_NN
includes_VPRT
2.7_CD
million_CD
relating_VBG
to_PIN
the_DT
reorganisation_NOMZ
of_PIN
some_QUAN
research_NN
and_PHC
development_NOMZ
operations_NOMZ
and_CC
other_JJ
business_NOMZ
functions_NOMZ
,_,
involving_VBG [PRESP]
some_QUAN
staff_NN
redundancies_VPRT
at_PIN
most_EMPH
sites_NN
._.
The_DT
reorganisation_NOMZ
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
be_VB [PASS]
completed_VBN
during_PIN
2004_CD
._.
A_DT
further_JJ
4.0_CD
million_CD
is_VPRT [BEMA]
in_PIN
respect_NN
of_PIN
the_DT
impairment_NOMZ
of_PIN
associated_VBN
intellectual_JJ
property_NN
and_CC
tangible_JJ
fixed_VBN
assets_NN
._.
In_CONJ
addition_NULL
,_,
1.6_CD
million_CD
relates_VPRT
to_PIN
a_DT
write_VB [PUBV]
down_RP
in_PIN
value_NN
of_PIN
fixed_JJ
asset_NN
investments_NOMZ
._.
5_CD
Operating_GER
loss_NN
profit_NN
Operating_GER
loss_NN
profit_NN
is_VPRT [PASS]
stated_VBN [PUBV]
after_IN
charging_VBG
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
fixed_JJ
assets_NN
owned_VBN
assets_NN
5,704_CD
5,616_CD
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
590_CD
485_CD
Amortisation_NOMZ
of_PIN
intangible_JJ
fixed_JJ
assets_NN
amortisation_NOMZ
of_PIN
goodwill_NN
4,072_CD
3,799_CD
amortisation_NOMZ
of_PIN
intellectual_JJ
property_NN
2,379_CD
2,483_CD
Research_NN
and_PHC
development_NOMZ
expenses_NN
current_JJ
year_NN
expenditure_NN
30,520_CD
29,285_CD
amortisation_NOMZ
of_PIN
deferred_VBN
expenditure_NN
218_CD
224_CD
Operating_GER
lease_NN
rentals_NN
hire_VB
of_PIN
plant_NN
and_PHC
machinery_NN
86_CD
434_CD
other_JJ
3,405_CD
3,336_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
62_CD
63_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
5_CD
Operating_GER
profit_NN
loss_NN
continued_VBD
Services_NN
provided_VBN [WZPAST]
by_PIN
the_DT
Groups_NN
auditor_NN
and_PHC
network_NN
firms_NN
It_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
policy_NN
to_TO
employ_VB
the_DT
auditors_NN
on_PIN
assignments_NOMZ
additional_JJ
to_PIN
their_TPP3
statutory_JJ
audit_NN
duties_NN
where_RB
their_TPP3
expertise_NN
and_PHC
experience_NN
with_PIN
the_DT
Group_NN
are_VPRT [BEMA]
important_PRED
,_,
principally_RB
tax_NN
advice_NN
and_CC
due_JJ
diligence_NN
reporting_VBG [PUBV] [WZPRES]
on_PIN
acquisitions_NOMZ
,_,
or_CC
where_RB
they_TPP3
are_VPRT [PASS]
awarded_VBN
assignments_NOMZ
on_PIN
a_DT
competitive_JJ
basis_NN
._.
During_PIN
the_DT
year_NN
the_DT
Group_NN
including_VBG [WZPRES]
its_PIT
overseas_PLACE
subsidiaries_NN
obtained_VBD
the_DT
following_JJ
services_NN
from_PIN
the_DT
Groups_NN
auditor_NN
at_PIN
costs_NN
detailed_VBN
below_PLACE
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Audit_NN
services_NN
statutory_JJ
audit_NN
326_CD
354_CD
audit_NN
related_VBN
regulatory_JJ
reporting_GER
145_CD
160_CD
Further_JJ
assurance_NN
services_NN
227_CD
418_CD
Tax_NN
services_NN
compliance_NN
services_NN
228_CD
86_CD
advisory_JJ
services_NN
523_CD
595_CD
Other_JJ
services_NN
not_XX0
covered_VBN
above_PLACE
25_CD
1,474_CD
1,613_CD
Included_VBN
in_PIN
the_DT
analysis_NN
above_PLACE
are_VPRT
Group_NN
audit_NN
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
auditor_NN
of_PIN
160,000_CD
2002_CD
:_:
194,000_CD
of_PIN
which_WDT [PIRE]
13,000_CD
2002_CD
:_:
13,000_CD
was_VBD [PASS]
paid_VBN
in_PIN
respect_NN
of_PIN
the_DT
parent_NN
company_NN
._.
Also_RB
included_VBN
above_PLACE
are_VPRT [PASS]
fees_NN
paid_VBN [WZPAST]
to_PIN
the_DT
Groups_NN
auditor_NN
in_PIN
respect_NN
of_PIN
non-audit_JJ
services_NN
in_PIN
the_DT
UK_NN
of_PIN
710,000_CD
2002_CD
:_:
990,000_CD
._.
6_CD
Employees_NN
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Employment_NOMZ
costs_NN
:_:
Wages_NN
and_PHC
salaries_NN
22,511_CD
20,614_CD
Social_NN
security_NOMZ
costs_NN
3,441_CD
3,091_CD
Pension_NN
costs_NN
1,769_CD
1,525_CD
27,721_CD
25,230_CD
The_DT
average_NN
monthly_JJ
number_NN
of_PIN
persons_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
including_VBG [WZPRES]
Executive_NN
Directors_NN
during_PIN
the_DT
year_NN
was_VBD
as_IN
follows_VPRT
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Pharmaceuticals_NN
476_CD
492_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
7_CD
Interest_NN
payable_JJ
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Interest_NN
payable_JJ
on_PIN
bank_NN
loans_NN
,_,
overdrafts_NN
and_CC
other_JJ
loans_NN
:_:
Repayable_JJ
within_PIN
five_CD
years_NN
,_,
not_XX0
by_PIN
instalments_NOMZ
93_CD
88_CD
Repayable_JJ
within_PIN
five_CD
years_NN
,_,
by_PIN
instalments_NOMZ
365_CD
112_CD
Repayable_JJ
wholly_RB
or_CC
partly_DWNT
in_PIN
more_EMPH
than_PIN
five_CD
years_NN
26_CD
373_CD
Finance_NN
leases_NN
70_CD
130_CD
Interest_NN
on_PIN
convertible_JJ
bonds_NN
3,939_CD
3,761_CD
4,493_CD
4,464_CD
8_CD
Taxation_NOMZ
Loss_NN
profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
,_,
as_IN
shown_VBN [PRIV]
in_PIN
the_DT
consolidated_JJ
profit_NN
and_PHC
loss_NN
account_NN
,_,
is_VPRT [PASS]
analyzed_VBN
between_PIN
its_PIT
component_NN
parts_NN
as_IN
follows_VPRT
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
UK_NN
821_CD
146_CD
Overseas_PLACE
42,162_CD
1,187_CD
42,983_CD
1,333_CD
Taxation_NOMZ
charge_NN
based_VBN [WZPAST]
on_PIN
loss_NN
profit_NN
for_PIN
the_DT
year_NN
:_:
Overseas_NN
taxation_NOMZ
240_CD
224_CD
Overseas_PLACE
taxation_NOMZ
relates_VPRT
principally_RB
to_TO
withholding_VBG
tax_NN
paid_VBN [WZPAST]
on_PIN
remittance_NN
of_PIN
royalties_NN
to_PIN
Switzerland_NN
which_WDT [WHSUB]
is_VPRT [BEMA]
not_XX0
recoverable_PRED
._.
There_EX
was_VBD
no_SYNE
deferred_JJ
tax_NN
component_NN
in_PIN
the_DT
tax_NN
charge_NN
for_PIN
the_DT
years_NN
presented_VBN
._.
The_DT
Group_NN
has_VPRT [PEAS]
estimated_VBN [PRIV]
total_JJ
tax_NN
losses_NN
available_JJ
to_TO
be_VB [PASS]
set_VBN
off_PIN
against_PIN
future_JJ
taxable_JJ
profits_NN
of_PIN
211.3_CD
million_CD
31_CD
December_NN
2002_CD
:_:
178.9_CD
million_CD
._.
These_DEMO
losses_NN
arise_VPRT
primarily_RB
in_PIN
the_DT
UK_NN
,_,
Switzerland_NN
and_PHC
US_FPP1
._.
Of_PIN
the_DT
211.3_CD
million_CD
of_PIN
losses_NN
carried_VBD
forward_RB
,_,
6.4_CD
million_CD
expire_VPRT
in_PIN
2004_CD
,_,
61.6_CD
million_CD
expire_VPRT
between_PIN
2005_CD
and_CC
2007_CD
,_,
136.4_CD
million_CD
expire_VPRT
from_PIN
2008_CD
onwards_NN
and_CC
6.9_CD
million_CD
of_PIN
losses_NN
may_POMD
be_VB [PASS]
carried_VBN
forward_RB
indefinitely_RB
._.
The_DT
above_PLACE
charges_NN
reconcile_VPRT
with_PIN
the_DT
applicable_JJ
UK_NN
statutory_JJ
corporation_NOMZ
tax_NN
rate_NN
as_IN
follows_VPRT
:_:
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
%_NN
%_NN
Statutory_NN
UK_NN
Corporation_NOMZ
tax_NN
rate_NN
30.0_CD
30.0_CD
Tax_NN
rate_NN
differences_NN
5.9_CD
18.2_CD
Permanent_JJ
differences_NN
1.2_CD
19.1_CD
Tax_NN
losses_NN
not_XX0
recognized_VBN [PRIV]
as_IN
deferred_JJ
tax_NN
assets_NN
22.1_CD
23.6_CD
Other_JJ
items_NN
not_XX0
recognized_VBN [PRIV]
as_IN
deferred_JJ
tax_NN
assets_NN
13.2_CD
26.9_CD
Effective_JJ
tax_NN
rate_NN
0.6_CD
16.8_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
64_CD
65_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
9_CD
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Attributable_JJ
loss_NN
profit_NN
before_IN
exceptional_JJ
items_NN
and_PHC
amortisation_NOMZ
27,067_CD
7,615_CD
Exceptional_JJ
items_NN
9,487_CD
Amortisation_NOMZ
6,669_CD
6,506_CD
Basic_JJ
and_PHC
diluted_JJ
attributable_JJ
loss_NN
profit_NN
43,223_CD
1,109_CD
000_CD
000_CD
Basic_JJ
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
609,855_CD
577,018_CD
Dilution_NOMZ
for_PIN
potential_JJ
Ordinary_NN
Shares_NN
20,077_CD
Diluted_NN
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
in_PIN
issue_NN
609,855_CD
597,095_CD
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
and_PHC
amortisation_NOMZ
4.4_CD
p_NN
1.3_CD
p_NN
Exceptional_JJ
items_NN
1.6_CD
p_NN
Amortisation_NOMZ
1.1_CD
p_NN
1.1_CD
p_NN
Basic_JJ
earnings_GER
per_PIN
Ordinary_NN
Share_NN
7.1_CD
p_JJ
0.2_CD
p_NN
Diluted_VBN
earnings_GER
per_PIN
Ordinary_NN
Share_NN
7.1_CD
p_JJ
0.2_CD
p_NN
In_PIN
2003_CD
there_EX
is_VPRT
no_SYNE
difference_NN
between_PIN
basic_JJ
and_PHC
diluted_JJ
earnings_GER
per_PIN
Ordinary_NN
Share_NN
since_OSUB
all_QUAN
potential_JJ
Ordinary_NN
Shares_NN
including_VBG [WZPRES]
convertible_JJ
bonds_NN
,_,
warrants_NN
and_PHC
options_NOMZ
are_VPRT [BEMA]
anti-dilutive_PRED
._.
For_PIN
diluted_VBN
earnings_GER
per_PIN
Ordinary_NN
Share_NN
in_PIN
2002_CD
,_,
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
issue_NN
is_VPRT [PASS]
adjusted_VBN
to_TO
assume_VB [PRIV]
conversion_NN
of_PIN
all_QUAN
dilutive_JJ
potential_JJ
Ordinary_NN
Shares_NN
._.
Shares_NN
held_VBN [PRIV] [WZPAST]
by_PIN
SkyePharma_NN
PLC_NN
General_NN
Employee_NN
Benefit_NN
Trust_NN
are_VPRT [PASS]
excluded_VBN
from_PIN
the_DT
weighted_JJ
average_JJ
number_NN
of_PIN
shares_NN
._.
The_DT
2.2_CD
million_CD
$_$
3.5_CD
million_CD
paid_VBN
to_PIN
Enzon_NN
for_PIN
access_NN
to_PIN
its_PIT
PEG_NN
modification_NOMZ
technology_NN
during_PIN
the_DT
year_NN
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
within_PIN
intellectual_JJ
property_NN
._.
Tangible_JJ
fixed_JJ
assets_NN
include_VPRT
net_JJ
book_NN
value_NN
of_PIN
2,011,000_CD
31_CD
December_NN
2002_CD
:_:
2,384,000_CD
in_PIN
respect_NN
of_PIN
assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
and_CC
hire_VB
purchase_NN
contracts_NN
._.
This_DEMP
comprises_VPRT
1,865,000_CD
in_PIN
respect_NN
of_PIN
laboratory_NN
equipment_NOMZ
and_PHC
machines_NN
,_,
19,000_CD
in_PIN
respect_NN
of_PIN
office_NN
and_CC
other_JJ
equipment_NOMZ
and_CC
127,000_CD
in_PIN
respect_NN
of_PIN
motor_NN
vehicles_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
66_CD
67_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
11_CD
Tangible_JJ
fixed_VBN
assets_NN
continued_VBD
Office_NN
and_PHC
Land_NN
and_CC
other_JJ
Motor_NN
buildings_GER
equipment_NOMZ
vehicles_NN
Total_JJ
Company_NN
000 000 000 000_CD
Cost_NN
At_PIN
1_CD
January_NN
2003 107 332_CD
75_CD
514_CD
Additions_NOMZ
117_CD
18_CD
Disposals_NN
75_CD
75_CD
At_PIN
31_CD
December_NN
2003 108 349 457_CD
Depreciation_NOMZ
At_PIN
1_CD
January_NN
2003_CD
76_CD
229_CD
75_CD
380_CD
Charge_NN
for_PIN
the_DT
year_NN
11_CD
37_CD
48_CD
Disposals_NN
75_CD
75_CD
At_PIN
31_CD
December_NN
2003 87 266 353_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2002 31 103 134_CD
Net_JJ
book_NN
value_NN
at_PIN
31_CD
December_NN
2003_CD
21_CD
83_CD
104_CD
12_CD
Fixed_VBN
asset_NN
investments_NOMZ
a_DT
Group_NN
Unlisted_NN
investments_NOMZ
Own_JJ
shares_NN
Total_JJ
000 000 000_CD
Cost_NN
At_PIN
1_CD
January_NN
2003_CD
18,874_CD
1,028_CD
19,902_CD
Exchange_NN
adjustments_NOMZ
87_CD
87_CD
Additions_NOMZ
4,836_CD
925_CD
5,761_CD
Charge_NN
for_PIN
the_DT
year_NN
558_CD
558_CD
Write_VB [PUBV]
down_RP
note_NN
4_CD
1,599_CD
1,599_CD
At_PIN
31_CD
December_NN
2003_CD
22,024_CD
1,395_CD
23,419_CD
Astralis_NN
Limited_NN
Astralis_NN
is_VPRT [BEMA]
an_DT
emerging_VBG
biotechnology_NN
company_NN
based_VBN [WZPAST]
in_PIN
the_DT
US_FPP1
,_,
and_ANDC
engaged_VBD
primarily_RB
in_PIN
the_DT
research_NN
and_PHC
development_NOMZ
of_PIN
novel_NN
treatments_NOMZ
for_PIN
immune_JJ
system_NN
disorders_NN
and_PHC
skin_NN
diseases_NN
._.
The_DT
company_NN
is_VPRT [SPAU]
currently_RB
developing_VBG
two_CD
products_NN
._.
Its_PIT
primary_JJ
product_NN
,_,
Psoraxine_NN
,_,
is_VPRT [BEMA]
an_DT
innovative_JJ
vaccine_NN
under_IN
development_NOMZ
for_PIN
the_DT
treatment_NOMZ
of_PIN
psoriasis_NN
._.
The_DT
companys_NN
second_JJ
product_NN
is_VPRT [BEMA]
for_PIN
the_DT
treatment_NOMZ
of_PIN
leishmaniasis_NN
._.
During_PIN
the_DT
year_NN
the_DT
Group_NN
acquired_VBD
250,000_CD
series_NN
A_DT
convertible_JJ
preferred_JJ
shares_NN
of_PIN
Astralis_NN
for_PIN
1.5_CD
million_CD
$_$
2.5_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
total_JJ
SkyePharma_NN
holding_GER
was_VBD [BEMA]
2_CD
million_CD
series_NN
A_DT
convertible_JJ
preferred_JJ
shares_NN
,_,
200,000_CD
common_JJ
shares_NN
and_CC
20,000_CD
warrants_NN
,_,
representing_VBG [PRESP]
approximately_RB
25.4_CD
%_NN
of_PIN
the_DT
common_JJ
shares_NN
assuming_VBG [PRIV] [WZPRES]
conversion_NN
of_PIN
the_DT
preferred_JJ
shares_NN
and_PHC
warrants_NN
._.
The_DT
investment_NOMZ
is_VPRT [PASS]
not_XX0
regarded_VBN
as_IN
an_DT
associated_VBN
undertaking_GER
as_IN
the_DT
Directors_NN
have_VPRT [PEAS]
concluded_VBN [PRIV]
that_THVC
the_DT
Group_NN
does_VPRT
not_XX0
exercise_VB
significant_JJ
influence_NN
._.
The_DT
convertible_JJ
preferred_JJ
shares_NN
,_,
common_JJ
shares_NN
and_PHC
warrants_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
a_DT
cost_NN
of_PIN
14.2_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
Astralis_NN
had_VBD
net_JJ
assets_NN
of_PIN
3.5_CD
million_CD
31_CD
December_NN
2002_CD
:_:
4.9_CD
million_CD
and_CC
a_DT
retained_VBN
loss_NN
for_PIN
the_DT
year_NN
of_PIN
3.1_CD
million_CD
2002_CD
:_:
12.2_CD
million_CD
._.
In_PIN
January_NN
2004_CD
SkyePharma_NN
converted_VBD
all_QUAN
of_PIN
its_PIT
2_CD
million_CD
series_NN
A_DT
convertible_JJ
preferred_JJ
shares_NN
into_PIN
25_CD
million_CD
common_JJ
shares_NN
,_,
12.5_CD
million_CD
of_PIN
these_DEMP
being_VBG [PASS]
held_VBN [PRIV]
in_PIN
escrow_NN
._.
The_DT
resulting_VBG
holding_GER
represents_VPRT
approximately_RB
35.7_CD
%_NN
of_PIN
the_DT
common_JJ
shares_NN
._.
Micap_NN
plc_NN
Micap_NN
is_VPRT [BEMA]
a_DT
UK_NN
science-based_JJ
technology_NN
company_NN
which_WDT [WHSUB]
was_VBD [PASS]
listed_VBN
on_PIN
the_DT
Alternative_NN
Investment_NOMZ
Market_NN
in_PIN
August_NN
2003_CD
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
12_CD
Fixed_VBN
asset_NN
investments_NOMZ
continued_VBD
During_PIN
the_DT
year_NN
the_DT
Group_NN
acquired_VBD
5,238,334_CD
ordinary_JJ
shares_NN
,_,
representing_VBG [PRESP]
approximately_RB
18.2_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
,_,
and_ANDC
1,830,000_CD
convertible_JJ
shares_NN
of_PIN
Micap_NN
for_PIN
2.1_CD
million_CD
._.
The_DT
shares_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
._.
Transition_NOMZ
Therapeutics_NN
Inc_NN
Transition_NOMZ
Therapeutics_NN
is_VPRT [BEMA]
a_DT
biopharmaceutical_JJ
company_NN
based_VBN [WZPAST]
in_PIN
Canada_NN
and_CC
engaged_VBN
primarily_RB
in_PIN
the_DT
business_NOMZ
of_PIN
developing_VBG
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
multiple_JJ
sclerosis_NN
,_,
diabetes_NN
and_PHC
restenosis_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
total_JJ
SkyePharma_NN
holding_GER
of_PIN
Transition_NOMZ
Therapeutics_NN
was_VBD [BEMA]
4,930,814_CD
shares_NN
,_,
representing_VBG [PRESP]
approximately_RB
6.6_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
._.
The_DT
shares_NN
are_VPRT [PASS]
recorded_VBN
at_PIN
a_DT
net_JJ
cost_NN
of_PIN
0.6_CD
million_CD
._.
Vital_JJ
Living_VBG
Inc_NN
Vital_NN
Living_VBG [WZPRES]
primarily_RB
develops_VPRT
and_PHC
markets_VPRT
evidence-based_JJ
nutriceuticals_NN
._.
These_DEMP
are_VPRT [PASS]
developed_VBN
for_PIN
incorporation_NOMZ
by_PIN
physicians_NN
into_PIN
a_DT
standard_JJ
physician_NN
patient_NN
program_NN
,_,
supported_VBN [PASTP]
by_PIN
a_DT
specially_RB
designed_VBN
compliance_NN
regimen_NN
._.
Vital_JJ
Living_VBG
is_VPRT [PASS]
based_VBN
in_PIN
the_DT
US_FPP1
._.
At_PIN
31_CD
December_NN
2002_CD
SkyePharma_NN
held_VBD [PRIV]
1_CD
million_CD
convertible_JJ
preference_NN
shares_NN
in_PIN
e-nutriceuticals_NN
Inc_NN
,_,
based_VBN [PASTP]
in_PIN
the_DT
US_FPP1
,_,
representing_VBG [PRESP]
approximately_RB
14.2_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
assuming_VBG [PRIV] [WZPRES]
conversion_NN
._.
In_PIN
August_NN
2003_CD
e-nutriceuticals_NN
merged_VBN [WZPAST]
with_PIN
Vital_JJ
Living_VBG
and_ANDC
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
merger_NN
SkyePharma_NN
acquired_VBD
14,204,548_CD
common_JJ
shares_NN
in_PIN
Vital_JJ
Living_VBG
._.
During_PIN
the_DT
year_NN
the_DT
Group_NN
acquired_VBD
1_CD
million_CD
series_NN
D_NN
convertible_JJ
preferred_JJ
shares_NN
,_,
$_$
1_CD
million_CD
of_PIN
12_CD
%_NN
senior_JJ
secured_VBN
convertible_JJ
notes_NN
due_JJ
2008_CD
and_CC
1_CD
million_CD
warrants_NN
expiring_VBG [WZPRES]
2008_CD
of_PIN
Vital_JJ
Living_VBG
for_PIN
1.2_CD
million_CD
$_$
2.0_CD
million_CD
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
total_JJ
SkyePharma_NN
holding_GER
was_VBD [BEMA]
14,204,548_CD
common_JJ
shares_NN
,_,
1_CD
million_CD
series_NN
D_NN
convertible_JJ
preferred_JJ
shares_NN
,_,
$_$
1_CD
million_CD
12_CD
%_NN
senior_JJ
secured_VBN
convertible_JJ
notes_NN
due_JJ
2008_CD
and_CC
1_CD
million_CD
warrants_NN
expiring_VBG [WZPRES]
2008_CD
,_,
representing_VBG [PRESP]
approximately_RB
24.4_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
,_,
28.1_CD
%_NN
assuming_VBG [PRIV] [WZPRES]
conversion_NN
of_PIN
the_DT
preferred_JJ
shares_NN
,_,
notes_NN
and_PHC
warrants_NN
._.
The_DT
investment_NOMZ
is_VPRT [PASS]
recorded_VBN
at_PIN
5.1_CD
million_CD
,_,
comprising_VBG
shares_NN
recorded_VBN [WZPAST]
at_PIN
Directors_NN
valuation_NOMZ
based_VBN [WZPAST]
on_PIN
a_DT
number_NN
of_PIN
considerations_NOMZ
including_VBG [WZPRES]
comparable_JJ
transactions_NOMZ
and_CC
discounted_JJ
future_JJ
cash_NN
flows_NN
,_,
and_ANDC
notes_NN
and_PHC
warrants_NN
recorded_VBN [WZPAST]
at_PIN
cost_NN
._.
The_DT
most_EMPH
recent_JJ
accounts_NN
available_JJ
are_VPRT [BEMA]
as_RB
at_PIN
30_CD
September_NN
2003_CD
when_RB
Vital_JJ
Living_VBG
had_VBD
net_JJ
assets_NN
of_PIN
27.8_CD
million_CD
and_CC
a_DT
retained_VBN
loss_NN
for_PIN
the_DT
nine_CD
month_NN
period_NN
of_PIN
10.1_CD
million_CD
._.
Cade_NN
Struktur_NN
Corp._NN
._.
Cade_NN
Struktur_NN
was_VBD [BEMA]
formerly_TIME
a_DT
drug_NN
delivery_NN
company_NN
engaged_VBD
in_PIN
research_NN
and_PHC
development_NOMZ
and_CC
worldwide_JJ
commercialisation_NOMZ
of_PIN
pharmaceutical_JJ
formulations_NOMZ
._.
The_DT
current_JJ
business_NOMZ
is_VPRT [BEMA]
the_DT
development_NOMZ
,_,
financing_GER
and_PHC
completion_NOMZ
of_PIN
industrial_JJ
and_CC
infrastructure_NN
projects_NN
in_PIN
Europe_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
total_JJ
SkyePharma_NN
holding_GER
of_PIN
Cade_NN
Struktur_NN
,_,
a_DT
Canadian_JJ
company_NN
,_,
was_VBD [BEMA]
869,086_CD
shares_NN
,_,
representing_VBG [PRESP]
approximately_RB
10.1_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
._.
The_DT
shares_NN
were_VBD [SPAU] [PASS]
originally_TIME
acquired_VBN
consequent_JJ
upon_PIN
the_DT
acquisition_NOMZ
of_PIN
the_DT
assets_NN
of_PIN
Hyal_NN
Pharmaceutical_NN
Corp._NN
._.
SkyePharma_NN
has_VPRT [PEAS]
not_XX0
attributed_VBN
a_DT
value_NN
to_PIN
these_DEMO
shares_NN
and_CC
they_TPP3
have_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
at_PIN
zero_CD
cost_NN
._.
Own_JJ
shares_NN
During_PIN
2001_CD
the_DT
Company_NN
established_VBD [PRIV]
an_DT
employee_NN
share_NN
ownership_NN
trust_NN
,_,
the_DT
SkyePharma_NN
PLC_NN
General_NN
Employee_NN
Benefit_NN
Trust_NN
._.
The_DT
purpose_NN
of_PIN
the_DT
trust_NN
is_VPRT
to_TO
hold_VB [PRIV]
shares_NN
in_PIN
the_DT
Company_NN
,_,
which_WDT [SERE]
may_POMD [SPAU]
subsequently_TIME
be_VB [PASS]
awarded_VBN
to_PIN
Directors_NN
and_PHC
employees_NN
under_IN
the_DT
Deferred_NN
Share_NN
Bonus_NN
Plan_NN
and_PHC
Share_NN
Purchase_NN
Plans_NN
._.
Further_JJ
details_NN
of_PIN
this_DEMO
plan_NN
are_VPRT [PASS]
provided_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
During_PIN
the_DT
year_NN
,_,
the_DT
trust_NN
purchased_VBD
2_CD
million_CD
shares_NN
and_CC
approximately_RB
1.1_CD
million_CD
shares_NN
were_VBD [PASS]
allocated_VBN
at_PIN
an_DT
average_JJ
price_NN
of_PIN
51_CD
pence_NN
per_PIN
share_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
trust_NN
held_VBD [PRIV]
approximately_RB
2.7_CD
million_CD
shares_NN
at_PIN
a_DT
carrying_VBG
value_NN
of_PIN
1.4_CD
million_CD
and_CC
a_DT
market_NN
value_NN
of_PIN
2.1_CD
million_CD
._.
b_NN
Company_NN
Shares_NN
in_PIN
Loans_NN
to_PIN
Group_NN
Group_NN
Unlisted_NN
Own_NN
undertakings_GER
undertakings_GER
investments_NOMZ
shares_NN
Total_JJ
000 000 000 000_CD
000_CD
At_PIN
1_CD
January_NN
2003_CD
202,176_CD
181,311_CD
12,696_CD
1,028_CD
397,211_CD
Additions_NOMZ
2,713_CD
18,000_CD
3,636_CD
925_CD
25,274_CD
Capitalisation_NOMZ
of_PIN
loans_NN
4,993_CD
4,993_CD
Charge_NN
for_PIN
the_DT
year_NN
558_CD
558_CD
At_PIN
31_CD
December_NN
2003_CD
209,882_CD
194,318_CD
16,332_CD
1,395_CD
421,927_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
68_CD
69_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
13_CD
Stock_NN
Group_NN
Group_NN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Raw_NN
materials_NN
and_PHC
consumables_NN
981_CD
919_CD
Work_NN
in_PIN
progress_NN
266_CD
263_CD
Finished_VBN
goods_NN
73_CD
74_CD
1,320_CD
1,256_CD
The_DT
replacement_NOMZ
cost_NN
of_PIN
stock_NN
is_VPRT
not_XX0
materially_RB
different_PRED
from_PIN
original_JJ
cost_NN
._.
14_CD
Debtors_NN
Group_NN
Group_NN
Company_NN
Company_NN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000 000_CD
000_CD
Trade_NN
debtors_NN
2,800_CD
26,327_CD
Amounts_NN
owed_VBN [WZPAST]
by_PIN
subsidiary_NN
undertakings_GER
5,481_CD
24,310_CD
Other_JJ
debtors_NN
2,953_CD
2,224_CD
103_CD
122_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
9,745_CD
6,502_CD
728_CD
1,465_CD
Interest_NN
receivable_NN
136 154 136 154_CD
15,634_CD
35,207_CD
6,448_CD
26,051_CD
15_CD
Current_JJ
Asset_NN
Investments_NOMZ
Current_JJ
asset_NN
investments_NOMZ
are_VPRT [BYPA]
represented_VBN
by_PIN
5_CD
%_NN
convertible_JJ
loan_NN
notes_NN
due_JJ
at_PIN
par_NN
,_,
together_RB
with_PIN
accrued_VBN
interest_NN
in_PIN
June_NN
2007_CD
._.
The_DT
notes_NN
were_VBD [PASS]
received_VBN
from_PIN
GeneMedix_NN
plc_NN
in_PIN
2002_CD
as_IN
an_DT
initial_JJ
payment_NOMZ
under_IN
an_DT
agreement_NOMZ
to_TO [SPIN]
jointly_RB
develop_VB
an_DT
extended_JJ
release_NN
formulation_NOMZ
of_PIN
Interferon_NN
alpha-2b_JJ
using_VBG
SkyePharmas_NN
DepoFoam_NN
technology_NN
._.
The_DT
notes_NN
are_VPRT [BEMA]
convertible_PRED
at_PIN
any_QUAN
time_NN
,_,
at_PIN
SkyePharmas_NN
option_NOMZ
,_,
into_PIN
between_PIN
approximately_RB
8.3_CD
million_CD
and_CC
11.2_CD
million_CD
GeneMedix_NN
ordinary_JJ
shares_NN
._.
There_EX
are_VPRT
no_SYNE
restrictions_NOMZ
or_CC
a_DT
lock-up_JJ
period_NN
on_PIN
conversion_NN
of_PIN
the_DT
notes_NN
._.
GeneMedix_NN
can_POMD
elect_VB
to_TO
redeem_VB
in_PIN
cash_NN
some_QUAN
or_CC
all_QUAN
of_PIN
the_DT
notes_NN
on_PIN
conversion_NN
._.
The_DT
notes_NN
have_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
and_CC
net_JJ
realisable_JJ
value_NN
assuming_VBG [PRIV] [WZPRES]
conversion_NN
._.
16_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
Group_NN
Group_NN
Company_NN
Company_NN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000 000_CD
000_CD
Bank_NN
overdrafts_NN
1,198_CD
Current_JJ
portion_NOMZ
of_PIN
bank_NN
loans_NN
note_VPRT [PRIV]
17_CD
2,342_CD
1,572_CD
761_CD
Current_JJ
portion_NOMZ
of_PIN
secured_JJ
mortgage_NN
note_NN
17 271 270_CD
Chiron_NN
promissory_JJ
note_NN
559_CD
Trade_NN
creditors_NN
5,915_CD
3,344_CD
337_CD
69_CD
Amounts_NN
owed_VBN [WZPAST]
to_PIN
subsidiary_NN
undertakings_GER
9,639_CD
10,229_CD
Corporation_NOMZ
tax_NN
3_CD
3_CD
Other_JJ
taxation_NOMZ
and_CC
social_JJ
security_NOMZ
costs_NN
1,628_CD
893_CD
221_CD
83_CD
Obligations_NOMZ
under_IN
hire_NN
purchase_NN
and_PHC
finance_NN
leases_NN
160_CD
1,085_CD
Deferred_JJ
income_NN
12,926_CD
15,069_CD
Accruals_NN
14,318_CD
12,235_CD
3,574_CD
3,431_CD
39,320_CD
34,471_CD
14,532_CD
13,812_CD
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
had_VBD
loans_NN
with_PIN
the_DT
Basellandschaftliche_NN
Kantonalbank_NN
of_PIN
0.9_CD
million_CD
CHF_NN
2_CD
million_CD
and_CC
0.7_CD
million_CD
CHF_NN
1.5_CD
million_CD
._.
These_DEMO
loans_NN
are_VPRT [BEMA]
renewable_JJ
annually_RB
and_CC
bear_VB
interest_NN
at_PIN
6.5_CD
%_NN
and_CC
6.0_CD
%_NN
respectively_RB
._.
The_DT
loans_NN
are_VPRT [PASS]
secured_VBN
on_PIN
the_DT
assets_NN
of_PIN
Jago_NN
and_CC
are_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
SkyePharma_NN
PLC._NN
._.
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
had_VBD
a_DT
promissory_JJ
note_NN
with_PIN
Chiron_NN
of_PIN
0.6_CD
million_CD
$_$
1_CD
million_CD
which_WDT
formed_VBD
part_NN
of_PIN
the_DT
consideration_NOMZ
for_PIN
the_DT
reacquisition_NOMZ
of_PIN
the_DT
US_FPP1
DepoCyt_NN
marketing_GER
,_,
distribution_NOMZ
and_PHC
sales_NN
rights_NN
._.
The_DT
promissory_JJ
note_NN
is_VPRT [BEMA]
repayable_PRED
in_PIN
June_NN
2004_CD
,_,
bearing_VBG
interest_NN
at_PIN
LIBOR_NN
plus_PIN
300_CD
points_NN
and_CC
is_VPRT [BYPA]
guaranteed_VBN [PUBV]
by_PIN
SkyePharma_NN
PLC._NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
17_CD
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Group_NN
Group_NN
Company_NN
Company_NN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000 000_CD
000_CD
Bank_NN
loans_NN
1,923_CD
1,923_CD
Secured_JJ
mortgage_NN
7,272_CD
7,502_CD
Chiron_NN
promissory_JJ
note_NN
621_CD
Accrued_VBN
rent_NN
3,459_CD
3,269_CD
Convertible_JJ
bonds_NN
due_JJ
2005_CD
58,791_CD
58,377_CD
58,791_CD
58,377_CD
Deferred_JJ
income_NN
2,948_CD
2,960_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
206_CD
235_CD
74,599_CD
72,964_CD
60,714_CD
58,377_CD
Bank_NN
and_CC
other_JJ
loans_NN
are_VPRT [BEMA]
repayable_PRED
as_IN
follows_VPRT
:_:
Between_PIN
one_CD
and_CC
two_CD
years_NN
1,171_CD
5,158_CD
900_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
1,247_CD
180_CD
977_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
318_CD
180_CD
46_CD
Between_PIN
four_CD
and_CC
five_CD
years_NN
271_CD
180_CD
After_IN
five_CD
years_NN
6,188_CD
2,425_CD
9,195_CD
8,123_CD
1,923_CD
Obligations_NOMZ
under_IN
finance_NN
leases_NN
are_VPRT [BEMA]
repayable_PRED
as_IN
follows_VPRT
:_:
Between_PIN
one_CD
and_CC
two_CD
years_NN
91_CD
97_CD
Between_PIN
two_CD
and_CC
three_CD
years_NN
96_CD
55_CD
Between_PIN
three_CD
and_CC
four_CD
years_NN
19 83 206 235_CD
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
had_VBD
a_DT
property_NN
mortgage_NN
facility_NOMZ
with_PIN
the_DT
Basellandschaftliche_NN
Kantonalbank_NN
of_PIN
7.5_CD
million_CD
CHF_NN
16.7_CD
million_CD
of_PIN
which_WDT [PIRE]
0.3_CD
million_CD
CHF_NN
0.6_CD
million_CD
is_VPRT [PASS]
shown_VBN [PRIV]
within_PIN
current_JJ
liabilities_NOMZ
._.
The_DT
mortgage_NN
is_VPRT [BEMA]
in_PIN
two_CD
tranches_NN
,_,
both_DT
secured_VBN
by_PIN
the_DT
assets_NN
of_PIN
Jago_NN
and_CC
guaranteed_VBN [PUBV]
by_PIN
SkyePharma_NN
PLC._NN
._.
The_DT
first_JJ
tranche_NN
of_PIN
3.2_CD
million_CD
CHF_NN
7.0_CD
million_CD
bears_NN
interest_NN
at_PIN
3.75_CD
%_NN
and_CC
is_VPRT [BEMA]
repayable_PRED
by_PIN
instalments_NOMZ
over_IN
21_CD
years_NN
semi-annually_RB
._.
The_DT
second_JJ
tranche_NN
of_PIN
4.3_CD
million_CD
CHF_NN
9.7_CD
million_CD
bears_NN
interest_NN
at_PIN
3.0_CD
%_NN
and_CC
is_VPRT [BEMA]
repayable_PRED
by_PIN
instalments_NOMZ
over_IN
51_CD
years_NN
._.
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Group_NN
had_VBD
a_DT
loan_NN
with_PIN
GE_NN
Capital_NN
Corp_NN
of_PIN
2.7_CD
million_CD
$_$
5_CD
million_CD
of_PIN
which_WDT [PIRE]
0.8_CD
million_CD
is_VPRT [PASS]
shown_VBN [PRIV]
within_PIN
current_JJ
liabilities_NOMZ
._.
The_DT
loan_NN
is_VPRT [BYPA]
secured_VBN
by_PIN
certain_JJ
assets_NN
of_PIN
SkyePharma_NN
Inc_NN
,_,
SkyePharma_NN
US_FPP1
Inc_NN
and_PHC
SkyePharma_NN
PLC._NN
._.
The_DT
loan_NN
bears_VPRT
interest_NN
at_PIN
8_CD
%_NN
and_CC
is_VPRT [BEMA]
repayable_PRED
by_PIN
instalments_NOMZ
from_PIN
2004_CD
until_IN
between_PIN
2005_CD
and_CC
2007_CD
._.
In_PIN
2000_CD
,_,
the_DT
Company_NN
issued_VBN
59.4_CD
million_CD
6_CD
%_NN
Convertible_JJ
Bonds_NN
the_DT
Bonds_NN
due_JJ
2005_CD
._.
The_DT
Bonds_NN
are_VPRT [BEMA]
convertible_PRED
at_PIN
the_DT
option_NOMZ
of_PIN
the_DT
holder_NN
into_PIN
Ordinary_NN
Shares_NN
at_PIN
a_DT
conversion_NN
price_NN
of_PIN
83_CD
pence_NN
at_PIN
any_QUAN
time_NN
up_RP
to_PIN
19_CD
June_NN
2005_CD
._.
Unless_COND
previously_TIME
redeemed_VBN
or_CC
converted_VBN
,_,
the_DT
Bonds_NN
will_PRMD
be_VB [BYPA]
redeemed_VBN
by_PIN
the_DT
Company_NN
at_PIN
their_TPP3
principal_JJ
amount_NN
on_PIN
19_CD
June_NN
2005_CD
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
70_CD
71_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
18_CD
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
National_NN
Restructuring_GER
Pension_NN
Insurance_NN
Total_NN
Group_NN
000 000 000 000_CD
At_PIN
1_CD
January_NN
2003 201 201_CD
Exchange_NN
adjustments_NOMZ
23_CD
30_CD
7_CD
Charge_NN
in_PIN
the_DT
year_NN
2,673_CD
54_CD
7_CD
2,734_CD
Utilised_NN
821_CD
821_CD
At_PIN
31_CD
December_NN
2003_CD
1,829_CD
285_CD
7_CD
2,121_CD
Restructuring_GER
provision_NN
The_DT
restructuring_GER
provision_NN
relates_VPRT
to_PIN
the_DT
reorganisation_NOMZ
of_PIN
research_NN
and_PHC
development_NOMZ
operations_NOMZ
and_CC
other_JJ
business_NOMZ
functions_NOMZ
involving_VBG [WZPRES]
reductions_NOMZ
in_PIN
staff_NN
at_PIN
most_EMPH
sites_NN
note_VPRT [PRIV]
4_CD
:_:
Exceptional_JJ
items_NN
._.
The_DT
remaining_VBG
provision_NN
of_PIN
approximately_RB
1.8_CD
million_CD
will_PRMD
be_VB [PASS]
utilised_VBN
in_PIN
2004_CD
._.
Pension_NN
provision_NN
The_DT
pension_NN
provision_NN
relates_VPRT
to_PIN
the_DT
retirement_NOMZ
commitments_NOMZ
under_IN
a_DT
defined_VBN
benefit_NN
scheme_NN
for_PIN
SkyePharma_NN
Production_NOMZ
SAS_NN
employees_NN
note_VPRT [PRIV]
26_CD
:_:
Pension_NN
Arrangements_NOMZ
._.
National_NN
Insurance_NN
provision_NN
A_DT
balance_NN
sheet_NN
provision_NN
of_PIN
7,000_CD
31_CD
December_NN
2002_CD
:_:
Nil_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
in_PIN
accordance_NN
with_PIN
UITF25_NN
:_:
National_NN
Insurance_NN
contributions_NOMZ
on_PIN
share_NN
option_NOMZ
gains_NN
._.
19_CD
Deferred_JJ
taxation_NOMZ
Group_NN
full_JJ
potential_JJ
Company_NN
full_JJ
potential_JJ
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000 000_CD
000_CD
Accelerated_VBN
capital_NN
allowances_NN
8,655_CD
4,848_CD
19_CD
42_CD
Other_JJ
timing_NN
differences_NN
8,485_CD
6,866_CD
18_CD
17_CD
UK_NN
tax_NN
benefits_NN
from_PIN
losses_NN
carried_VBD
forward_RB
2,063_CD
1,288_CD
2,063_CD
1,288_CD
Overseas_PLACE
tax_NN
benefits_NN
from_PIN
losses_NN
carried_VBD
forward_RB
36,607_CD
29,731_CD
Potential_JJ
deferred_JJ
tax_NN
asset_NN
55,810_CD
42,733_CD
2,100_CD
1,347_CD
No_DT
deferred_VBN
tax_NN
asset_NN
is_VPRT [PASS]
recognized_VBN [PRIV]
,_,
given_VBN
the_DT
uncertainty_NN
of_PIN
the_DT
recoverability_NOMZ
of_PIN
the_DT
Groups_NN
tax_NN
losses_NN
carried_VBD
forward_RB
._.
20_CD
Contingent_JJ
liabilities_NOMZ
and_PHC
guarantees_NN
At_PIN
31_CD
December_NN
2003_CD
the_DT
Company_NN
had_VBD [PEAS]
provided_VBN
guarantees_NN
on_PIN
various_JJ
bank_NN
borrowings_GER
of_PIN
its_PIT
subsidiaries_NN
as_IN
set_VBN
out_PIN
in_PIN
note_NN
16_CD
:_:
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
within_PIN
one_CD
year_NN
and_PHC
note_NN
17_CD
:_:
Creditors_NN
:_:
amounts_NN
falling_VBG [WZPRES]
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
._.
In_PIN
common_JJ
with_PIN
most_EMPH
business_NOMZ
enterprises_NN
,_,
Group_NN
companies_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
a_DT
number_NN
of_PIN
claims_NN
from_PIN
third_JJ
parties_NN
,_,
the_DT
outcome_NN
of_PIN
which_WDT [PIRE]
can_POMD
not_XX0
at_PIN
present_JJ
be_VB [PASS]
determined_VBN [SUAV] [PRIV]
but_CC
which_WDT
are_VPRT [PASS]
not_XX0
considered_VBN [PRIV]
to_TO
be_VB
material_NN
in_PIN
the_DT
context_NN
of_PIN
these_DEMO
Financial_NN
Statements_NOMZ
._.
Provision_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
in_PIN
these_DEMO
accounts_NN
for_PIN
any_QUAN
liabilities_NOMZ
which_WDT [WHSUB]
are_VPRT [PASS]
expected_VBN [PRIV]
to_TO
materialise_VB
from_PIN
such_JJ
claims_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
21_CD
Commitments_NOMZ
Group_NN
Group_NN
Company_NN
Company_NN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000 000_CD
000_CD
Capital_NN
commitments_NOMZ
Contracted_VBN [WZPAST]
for_PIN
but_CC
not_XX0
provided_VBN
in_PIN
the_DT
accounts_NN
197_CD
Commitments_NOMZ
under_IN
operating_VBG
leases_NN
to_TO
pay_VB
rentals_NN
for_PIN
the_DT
next_JJ
year_NN
Operating_VBG [WZPRES]
leases_NN
on_PIN
land_NN
and_PHC
buildings_GER
which_WDT [WHSUB]
expire_VPRT
:_:
In_PIN
one_CD
year_NN
or_CC
less_JJ
50_CD
28_CD
In_PIN
two_CD
to_PIN
five_CD
years_NN
583 707 583 566_CD
In_PIN
five_CD
years_NN
or_CC
more_EMPH
2,832_CD
1,816_CD
3,415_CD
2,573_CD
583_CD
594_CD
Other_JJ
operating_GER
leases_NN
which_WDT [WHSUB]
expire_VPRT
:_:
In_PIN
one_CD
year_NN
or_CC
less_JJ
7_CD
18_CD
7_CD
5_CD
In_PIN
two_CD
to_PIN
five_CD
years_NN
38_CD
53_CD
12_CD
11_CD
45_CD
71_CD
19_CD
16_CD
In_CONJ
addition_NULL
the_DT
Group_NN
has_VPRT [PEAS]
committed_VBN
to_TO
undertake_VB
certain_JJ
clinical_JJ
trials_NN
on_PIN
behalf_NN
of_PIN
its_PIT
partners_NN
under_IN
development_NOMZ
and_PHC
licensing_GER
agreements_NOMZ
._.
The_DT
Group_NN
is_VPRT [PASS]
committed_VBN
to_TO
make_VB
certain_JJ
payments_NOMZ
to_PIN
third_JJ
parties_NN
contingent_JJ
upon_PIN
future_JJ
events_NN
such_JJ
as_IN
the_DT
approval_NN
and_PHC
launch_NN
of_PIN
products_NN
._.
22_CD
Share_NN
capital_NN
Equity_NOMZ
share_NN
capital_NN
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
31_CD
December_NN
2003_CD
31_CD
December_NN
2002_CD
Number_NN
of_PIN
shares_NN
Number_NN
of_PIN
shares_NN
000_CD
000_CD
Authorised_NN
Ordinary_NN
Shares_NN
of_PIN
10p_CD
each_QUAN
1,114,000,000_CD
1,114,000,000_CD
111,400_CD
111,400_CD
Ordinary_NN
shares_NN
of_PIN
Nominal_NN
10p_CD
each_QUAN
Value_NN
Number_NN
000_CD
Issued_VBN
,_,
allotted_VBN
and_CC
fully_AMP
paid_VBN
At_PIN
1_CD
January_NN
2002_CD
560,023,339_CD
56,002_CD
Exercise_NN
of_PIN
B_NN
Warrants_NN
2,051,607_CD
205_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
1,323,853_CD
133_CD
Issue_NN
of_PIN
shares_NN
in_PIN
respect_NN
of_PIN
RTP_NN
Pharma_NN
Inc._NN
8,059,268_CD
806_CD
Issue_NN
of_PIN
shares_NN
to_PIN
Kowa_NN
Company_NN
Limited_NN
30,000,000_CD
3,000_CD
Conversion_NN
of_PIN
Deferred_NN
A_NN
Shares_NN
12,000,000_CD
1,200_CD
At_PIN
31_CD
December_NN
2002_CD
613,458,067_CD
61,346_CD
Exercise_NN
of_PIN
share_NN
options_NOMZ
1,521,662_CD
152_CD
Issue_NN
of_PIN
shares_NN
in_PIN
respect_NN
of_PIN
RTP_NN
Pharma_NN
Inc._NN
3,690,211_CD
369_CD
At_PIN
31_CD
December_NN
2003_CD
618,669,940_CD
61,867_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
72_CD
73_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
22_CD
Share_NN
capital_NN
continued_VBD
As_IN
part_NN
of_PIN
the_DT
2001_CD
RTP_NN
acquisition_NOMZ
,_,
deferred_VBN
consideration_NOMZ
of_PIN
3,690,211_CD
SkyePharma_NN
Ordinary_NN
Shares_NN
were_VBD [PASS]
issued_VBN
to_PIN
the_DT
former_JJ
RTP_NN
shareholders_NN
during_PIN
the_DT
year_NN
._.
The_DT
cash_NN
consideration_NOMZ
received_VBN [WZPAST]
on_PIN
the_DT
issue_NN
of_PIN
Ordinary_NN
Shares_NN
during_PIN
the_DT
year_NN
amounted_VBD
to_PIN
1,437,000_CD
2002_CD
:_:
26,168,000_CD
._.
Non-equity_JJ
share_NN
capital_NN
Deferred_VBN
B_NN
Shares_NN
of_PIN
Nominal_NN
10p_CD
each_QUAN
Value_NN
Number_NN
000_CD
Authorised_NN
and_CC
issued_VBN
At_PIN
1_CD
January_NN
2003_CD
and_CC
31_CD
December_NN
2003_CD
12,000,000_CD
1,200_CD
12_CD
million_CD
Deferred_NN
A_NN
and_CC
12_CD
million_CD
Deferred_NN
B_NN
Shares_NN
were_VBD [PASS]
issued_VBN
to_PIN
Dr_NN
Gonella_NN
,_,
the_DT
vendor_NN
of_PIN
Jago_NN
,_,
on_PIN
20_CD
July_NN
2000_CD
under_IN
the_DT
Settlement_NOMZ
Agreement_NOMZ
that_TSUB
established_VBD [PRIV]
the_DT
full_JJ
and_PHC
final_JJ
settlement_NOMZ
of_PIN
the_DT
deferred_JJ
consideration_NOMZ
payable_JJ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
._.
The_DT
holders_NN
of_PIN
Deferred_NN
A_NN
and_PHC
B_NN
Shares_NN
have_VPRT
no_SYNE
rights_NN
to_TO
participate_VB
in_PIN
the_DT
profits_NN
of_PIN
the_DT
Company_NN
,_,
no_SYNE
voting_NN
rights_NN
and_CC
on_PIN
a_DT
winding_VBG
up_RP
or_CC
other_JJ
return_NN
of_PIN
capital_NN
only_DWNT
receive_VB
the_DT
nominal_JJ
value_NN
of_PIN
their_TPP3
shares_NN
if_COND
the_DT
holders_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
the_DT
capital_NN
of_PIN
the_DT
Company_NN
have_VPRT [PEAS]
received_VBN
the_DT
sum_NN
of_PIN
1_CD
million_CD
per_PIN
Ordinary_NN
Share_NN
and_CC
,_,
as_IN
such_JJ
,_,
are_VPRT [PASS]
classified_VBN
as_IN
non-equity_JJ
shares_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
the_DT
Settlement_NOMZ
Agreement_NOMZ
,_,
following_VBG [PRESP]
the_DT
US_FPP1
launch_NN
and_CC
first_JJ
commercial_JJ
sale_NN
of_PIN
Paxil_NN
CR_NN
by_PIN
GlaxoSmithKline_NN
in_PIN
2002_CD
,_,
the_DT
12_CD
million_CD
Deferred_NN
A_NN
Shares_NN
were_VBD [SPAU] [PASS]
automatically_RB
converted_VBN
into_PIN
12_CD
million_CD
Ordinary_NN
Shares_NN
._.
The_DT
12_CD
million_CD
Deferred_NN
B_NN
Shares_NN
automatically_RB
convert_VPRT
to_PIN
12_CD
million_CD
Ordinary_NN
Shares_NN
on_PIN
the_DT
Companys_NN
receipt_NN
of_PIN
a_DT
royalty_NN
statement_NOMZ
under_IN
the_DT
current_JJ
Licence_NN
Agreement_NOMZ
stating_VBG [PUBV] [THATD] [WZPRES]
that_DEMP
reported_VBD [PUBV]
sales_NN
of_PIN
Paroxetine_NN
Paxil_NN
in_PIN
combination_NOMZ
with_PIN
the_DT
Geomatrix_NN
technology_NN
have_VPRT [PEAS]
exceeded_VBN
$_$
1,000_CD
million_CD
during_PIN
any_QUAN
calendar_NN
period_NN
prior_RB
to_PIN
1_CD
January_NN
2006_CD
or_CC
exceeded_VBD
$_$
337_CD
million_CD
between_PIN
1_CD
January_NN
2006_CD
and_CC
3_CD
May_POMD
2006_CD
._.
In_PIN
the_DT
event_NN
that_DEMP
this_DEMO
condition_NOMZ
is_VPRT [BEMA]
not_XX0
satisfied_JJ
prior_RB
to_PIN
3_CD
May_POMD
2006_CD
,_,
the_DT
Deferred_NN
B_NN
Shares_NN
will_PRMD
not_XX0
be_VB [PASS]
converted_VBN
and_CC
will_PRMD
be_VB [PASS]
canceled_VBN
._.
The_DT
vendor_NN
will_PRMD
not_XX0
be_VB [PASS]
entitled_VBN
to_PIN
any_QUAN
other_JJ
nor_SYNE
additional_JJ
compensation_NOMZ
._.
The_DT
Deferred_JJ
A_DT
and_CC
B_NN
Shares_NN
were_VBD [PASS]
issued_VBN
on_PIN
20_CD
July_NN
2000_CD
when_RB
the_DT
price_NN
of_PIN
an_DT
Ordinary_NN
Share_NN
was_VBD [BEMA]
94.25_CD
pence_NN
._.
The_DT
difference_NN
between_PIN
the_DT
nominal_JJ
value_NN
of_PIN
the_DT
Deferred_NN
B_NN
Shares_NN
and_CC
their_TPP3
fair_JJ
value_NN
,_,
taken_VBN
to_TO
be_VB [BEMA]
94.25_CD
pence_NN
,_,
at_PIN
issue_NN
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
as_IN
non-equity_JJ
share_NN
premium_NN
._.
Warrants_NN
The_DT
Company_NN
has_VPRT
the_DT
following_JJ
warrants_NN
outstanding_JJ
:_:
a_DT
D_NN
and_PHC
E_NN
warrants_NN
The_DT
D_NN
and_PHC
E_NN
Warrants_NN
were_VBD [PASS]
issued_VBN
in_PIN
March_NN
2002_CD
as_IN
part_NN
of_PIN
the_DT
consideration_NOMZ
for_PIN
the_DT
agreement_NOMZ
with_PIN
Paul_NN
Capital_NN
to_TO
fund_VB
new_JJ
product_NN
development_NOMZ
._.
The_DT
D_NN
and_PHC
E_NN
Warrants_NN
entitle_VPRT
the_DT
holders_NN
to_TO
subscribe_VB
for_PIN
a_DT
total_NN
of_PIN
5_CD
million_CD
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
to_PIN
31_CD
December_NN
2008_CD
at_PIN
an_DT
exercise_NN
price_NN
of_PIN
73.75_CD
pence_NN
per_PIN
Ordinary_NN
Share_NN
._.
A_DT
value_NN
of_PIN
0.3_CD
million_CD
has_VPRT [PEAS]
been_VBN [PASS]
attributed_VBN
to_PIN
the_DT
D_NN
and_PHC
E_NN
Warrants_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
within_PIN
Other_JJ
Reserves_NN
._.
b_NN
F_NN
warrants_NN
The_DT
F_NN
Warrants_NN
were_VBD [PASS]
issued_VBN
in_PIN
December_NN
2003_CD
as_IN
part_NN
of_PIN
the_DT
2.7_CD
million_CD
$_$
5_CD
million_CD
loan_NN
with_PIN
GE_NN
Capital_NN
Corp._NN
._.
The_DT
F_NN
Warrants_NN
entitle_VPRT
the_DT
holders_NN
to_TO
subscribe_VB
for_PIN
a_DT
total_NN
of_PIN
300,000_CD
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
until_IN
the_DT
repayment_NOMZ
date_NN
of_PIN
the_DT
loan_NN
at_PIN
an_DT
exercise_NN
price_NN
of_PIN
1.20_CD
per_PIN
Ordinary_NN
Share_NN
._.
A_DT
value_NN
of_PIN
39,000_CD
has_VPRT [PEAS]
been_VBN [PASS]
attributed_VBN
to_PIN
the_DT
F_NN
Warrants_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
within_PIN
Other_JJ
Reserves_NN
._.
c_NN
Other_JJ
warrants_NN
Warrants_NN
were_VBD [PASS]
issued_VBN
in_PIN
December_NN
1999_CD
as_IN
part_NN
of_PIN
the_DT
acquisition_NOMZ
of_PIN
DepoTech_NN
and_CC
entitle_VB
the_DT
holders_NN
to_TO
subscribe_VB
for_PIN
291,777_CD
Ordinary_NN
Shares_NN
at_PIN
any_QUAN
time_NN
during_PIN
the_DT
period_NN
beginning_VBG [WZPRES]
31_CD
December_NN
1999_CD
and_CC
ending_VBG
on_PIN
25_CD
February_NN
2005_CD
at_PIN
an_DT
exercise_NN
price_NN
of_PIN
$_$
1.453_CD
90.25_CD
pence_NN
per_PIN
Ordinary_NN
Share_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
22_CD
Share_NN
capital_NN
continued_VBD
Share_NN
options_NOMZ
The_DT
Company_NN
encourages_VPRT
employee_NN
participation_NOMZ
in_PIN
its_PIT
shares_NN
through_PIN
ownership_NN
and_CC
continues_VPRT
to_TO
operate_VB
various_JJ
Share_NN
Option_NOMZ
Schemes_NN
and_CC
the_DT
Unapproved_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
Under_IN
the_DT
terms_NN
of_PIN
these_DEMO
Schemes_NN
the_DT
Board_NN
may_POMD
offer_VB
options_NOMZ
to_TO
purchase_VB
Ordinary_NN
Shares_NN
in_PIN
the_DT
Company_NN
to_PIN
employees_NN
,_,
including_VBG
Directors_NN
,_,
at_PIN
a_DT
price_NN
not_XX0
less_JJ
than_PIN
the_DT
higher_JJ
of_PIN
the_DT
nominal_JJ
value_NN
and_CC
the_DT
market_NN
value_NN
of_PIN
the_DT
shares_NN
on_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
UK_NN
and_CC
European_JJ
employees_NN
are_VPRT [BEMA]
only_DWNT
exercisable_PRED
between_PIN
the_DT
third_JJ
and_CC
tenth_NN
anniversary_NN
of_PIN
the_DT
date_NN
of_PIN
grant_NN
,_,
and_ANDC
are_VPRT [BEMA]
subject_PRED
to_PIN
the_DT
Companys_NN
Code_NN
of_PIN
Conduct_NN
for_PIN
dealing_VBG
in_PIN
Shares_NN
,_,
and_ANDC
the_DT
Model_NN
Code_NN
._.
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
US_FPP1
employees_NN
prior_RB
to_PIN
2001_CD
vest_NN
at_PIN
25_CD
%_NN
per_PIN
annum_NN
from_PIN
the_DT
date_NN
of_PIN
grant_NN
and_CC
there_EX
were_VBD
no_SYNE
performance_NN
criteria_NN
._.
UK_NN
and_CC
European_JJ
options_NOMZ
granted_VBN [SUAV] [WZPAST]
prior_RB
to_PIN
2001_CD
may_POMD [SPAU]
only_DWNT
be_VB [PASS]
exercised_VBN
if_COND
the_DT
growth_NN
in_PIN
the_DT
Companys_NN
share_NN
price_NN
over_IN
a_DT
consecutive_JJ
three-year_JJ
period_NN
exceeds_VPRT
the_DT
growth_NN
over_IN
the_DT
same_JJ
period_NN
in_PIN
the_DT
FT-SE_NN
All_QUAN
Share_NN
Index_NN
._.
This_DEMO
criteria_NN
was_VBD [PASS]
satisfied_VBN
for_PIN
the_DT
first_JJ
time_NN
in_PIN
March_NN
2000_CD
._.
Employees_NN
with_PIN
options_NOMZ
that_TSUB
are_VPRT [BEMA]
within_PIN
their_TPP3
exercise_NN
period_NN
are_VPRT [BEMA]
now_TIME
able_PRED
to_TO
exercise_VB
those_DEMO
options_NOMZ
within_PIN
any_QUAN
one-year_JJ
period_NN
from_PIN
the_DT
date_NN
the_DT
performance_NN
condition_NOMZ
is_VPRT [PASS]
satisfied_VBN
._.
Super_NN
Options_NOMZ
are_VPRT [BEMA]
exercisable_PRED
after_IN
five_CD
years_NN
and_CC
are_VPRT [BEMA]
subject_PRED
to_PIN
higher_JJ
performance_NN
conditions_NOMZ
in_PIN
accordance_NN
with_PIN
those_DEMP
recommended_VBN [SUAV]
by_PIN
the_DT
Association_NOMZ
of_PIN
British_NN
Insurers_NN
._.
Following_VBG
changes_NN
to_PIN
the_DT
option_NOMZ
plans_VPRT
approved_VBN
at_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
June_NN
2001_CD
,_,
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
Directors_NN
and_CC
senior_JJ
employees_NN
since_OSUB
that_DEMO
date_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
linked_VBN [WZPAST]
to_PIN
the_DT
total_JJ
shareholder_NN
return_NN
of_PIN
a_DT
comparator_NN
group_NN
of_PIN
companies_NN
,_,
and_ANDC
are_VPRT [BEMA]
not_XX0
subject_PRED
to_TO
retesting_VBG
._.
Options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
other_JJ
US_FPP1
employees_NN
continue_VPRT
to_PIN
vest_NN
at_PIN
25_CD
%_NN
per_PIN
annum_NN
with_PIN
no_SYNE
performance_NN
criteria_NN
,_,
and_ANDC
other_JJ
European_JJ
employees_NN
who_WP [WHSUB]
are_VPRT
not_XX0
Directors_NN
or_CC
senior_JJ
employees_NN
can_POMD
exercise_VB
their_TPP3
options_NOMZ
after_IN
three_CD
years_NN
and_CC
are_VPRT [BEMA]
not_XX0
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
._.
The_DT
Groups_NN
plans_NN
are_VPRT [BEMA]
further_PRED
detailed_VBN
in_PIN
the_DT
Remuneration_NOMZ
Report_NN
._.
The_DT
market_NN
value_NN
of_PIN
Ordinary_NN
Shares_NN
during_PIN
2003_CD
ranged_VBD
from_PIN
the_DT
lowest_JJ
closing_GER
mid-price_NN
of_PIN
41.5_CD
pence_NN
to_PIN
the_DT
highest_JJ
closing_GER
mid-price_NN
of_PIN
79.25_CD
pence_NN
per_PIN
share_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
74_CD
75_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
22_CD
Share_NN
capital_NN
continued_VBD
At_PIN
31_CD
December_NN
2003_CD
the_DT
following_VBG
Ordinary_NN
Shares_NN
were_VBD
under_IN
option_NOMZ
to_PIN
employees_NN
or_CC
former_JJ
employees_NN
of_PIN
the_DT
Group_NN
:_:
Option_NOMZ
price_NN
for_PIN
each_QUAN
Number_NN
of_PIN
options_NOMZ
over_IN
Expiry_NN
date_NN
Ordinary_NN
Share_NN
of_PIN
10p_CD
Ordinary_NN
Shares_NN
of_PIN
10p_CD
29_CD
April_NN
2006_CD
75.0_CD
p_NN
1,427,676_CD
28_CD
May_POMD
2006_CD
92.0_CD
p_NN
417,255_CD
6_CD
December_NN
2006_CD
81.0_CD
p_NN
1,234,568_CD
7_CD
April_NN
2007_CD
66.5_CD
p_NN
631,318_CD
28_CD
January_NN
2008_CD
51.0_CD
p_NN
124,073_CD
31_CD
March_NN
2008_CD
93.0_CD
p_NN
796,362_CD
5_CD
October_NN
2008_CD
44.8_CD
p_NN
627,770_CD
19_CD
April_NN
2009_CD
69.5_CD
p_NN
3,207,840_CD
25_CD
May_POMD
2009_CD
56.7_CD
p_NN
7,797,226_CD
7_CD
September_NN
2009_CD
56.9_CD
p_NN
191,066_CD
6_CD
June_NN
2010_CD
91.3_CD
p_NN
848,480_CD
3_CD
November_NN
2010_CD
81.7_CD
p_NN
1,595,526_CD
12_CD
June_NN
2011_CD
80.6_CD
p_NN
6,092,141_CD
31_CD
October_NN
2011_CD
55.6_CD
p_NN
1,194,924_CD
24_CD
December_NN
2011_CD
55.1_CD
p_NN
552,514_CD
12_CD
April_NN
2012_CD
72.3_CD
p_NN
8,359,909_CD
24_CD
May_POMD
2012_CD
78.6_CD
p_NN
515,653_CD
25_CD
September_NN
2012_CD
51.7_CD
p_NN
1,226,189_CD
7_CD
April_NN
2013_CD
46.5_CD
p_NN
15,142,062_CD
26_CD
September_NN
2013_CD
62.0_CD
p_NN
362,666_CD
52,345,218_CD
23_CD
Shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
Group_NN
and_PHC
Company_NN
000_CD
At_PIN
1_CD
January_NN
2003_CD
and_CC
31_CD
December_NN
2003_CD
a_DT
Krypton_NN
The_NN
deferred_JJ
consideration_NOMZ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Krypton_NN
provides_VPRT
that_DEMO
a_DT
maximum_NN
of_PIN
37.5_CD
million_CD
Ordinary_NN
Shares_NN
would_PRMD
be_VB [PASS]
issued_VBN
contingent_NN
on_PIN
a_DT
change_NN
in_PIN
control_NN
of_PIN
the_DT
Company_NN
at_PIN
a_DT
share_NN
price_NN
of_PIN
not_XX0
less_JJ
than_PIN
80_CD
pence_NN
compounded_VBN [WZPAST]
at_PIN
an_DT
annual_JJ
rate_NN
of_PIN
10_CD
%_NN
1.71_CD
as_RB
at_PIN
31_CD
December_NN
2003_CD
,_,
or_CC
satisfaction_NOMZ
of_PIN
various_JJ
conditions_NOMZ
and_PHC
hurdles_NN
which_WDT [WHSUB]
lapsed_VBD
on_PIN
31_CD
December_NN
2003_CD
._.
No_SYNE
provision_NN
for_PIN
deferred_JJ
consideration_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
as_IN
at_PIN
31_CD
December_NN
2003_CD
._.
b_NN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
In_PIN
March_NN
2002_CD
the_DT
Group_NN
announced_VBD [PUBV]
a_DT
second_JJ
transaction_NOMZ
with_PIN
Paul_NN
Capital_NN
Royalty_NN
Acquisition_NOMZ
Fund_NN
under_IN
which_WDT
SkyePharma_NN
will_PRMD
issue_VB
Ordinary_NN
Shares_NN
up_IN
to_PIN
a_DT
value_NN
of_PIN
$_$
7.5_CD
million_CD
if_COND
royalties_NN
and_PHC
milestones_NN
received_VBN [WZPAST]
by_PIN
SkyePharma_NN
in_PIN
respect_NN
of_PIN
those_DEMO
products_NN
included_VBD
in_PIN
the_DT
transaction_NOMZ
are_VPRT [BEMA]
not_XX0
in_PIN
excess_NN
of_PIN
minimum_JJ
annual_JJ
payments_NOMZ
required_VBN [SUAV]
to_TO
be_VB [PASS]
made_VBN
to_PIN
Paul_NN
Capital_NN
._.
During_PIN
2003_CD
the_DT
royalties_NN
received_VBN [WZPAST]
by_PIN
SkyePharma_NN
were_VBD [BEMA]
substantially_RB
in_PIN
excess_NN
of_PIN
the_DT
minimum_JJ
payments_NOMZ
required_VBN [SUAV]
to_TO
be_VB [PASS]
made_VBN
to_PIN
Paul_NN
Capital_NN
,_,
consequently_CONJ
the_DT
company_NN
has_VPRT [PEAS]
not_XX0
provided_VBN
for_PIN
any_QUAN
additional_JJ
obligations_NOMZ
under_IN
this_DEMO
provision_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
24_CD
Reserves_NN
Equity_NOMZ
Non-equity_NOMZ
Profit_NN
and_PHC
share_NN
share_NN
Other_JJ
loss_NN
premium_NN
premium_NN
reserves_NN
account_VPRT
Group_NN
000 000 000 000_CD
At_PIN
1_CD
January_NN
2003_CD
306,309_CD
10,110_CD
9,311_CD
264,006_CD
Exchange_NN
adjustments_NOMZ
175_CD
On_PIN
issue_NN
of_PIN
shares_NN
and_PHC
warrants_NN
2,191_CD
39_CD
On_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
613_CD
Loss_NN
for_PIN
the_DT
year_NN
43,223_CD
Unrealised_NN
gain_NN
on_PIN
contract_NN
development_NOMZ
2,029_CD
At_PIN
31_CD
December_NN
2003_CD
309,113_CD
10,110_CD
9,350_CD
305,375_CD
Other_JJ
reserves_NN
relate_VPRT
to_PIN
a_DT
merger_NN
reserve_NN
on_PIN
acquisition_NOMZ
and_CC
a_DT
warrant_NN
reserve_NN
on_PIN
the_DT
issue_NN
of_PIN
the_DT
D_NN
,_,
E_NN
and_PHC
F_NN
Warrants_NN
._.
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
cumulative_JJ
amount_NN
of_PIN
goodwill_NN
eliminated_VBN [WZPAST]
against_PIN
reserves_NN
was_VBD [BEMA]
147,632,000_CD
2002_CD
:_:
147,632,000_CD
._.
Equity_NOMZ
Non-equity_NOMZ
Profit_NN
and_PHC
share_NN
share_NN
Other_JJ
loss_NN
premium_NN
premium_NN
reserves_NN
account_VPRT
Company_NN
000 000 000 000_CD
At_PIN
1_CD
January_NN
2003_CD
306,309_CD
10,110_CD
9,311_CD
16,348_CD
On_PIN
issue_NN
of_PIN
shares_NN
and_PHC
warrants_NN
2,191_CD
39_CD
On_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
613_CD
Loss_NN
for_PIN
the_DT
year_NN
821_CD
At_PIN
31_CD
December_NN
2003_CD
309,113_CD
10,110_CD
9,350_CD
17,169_CD
As_IN
permitted_VBN
by_PIN
Section_NOMZ
230_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
the_DT
Profit_NN
and_PHC
Loss_NN
Account_NN
of_PIN
the_DT
Company_NN
is_VPRT [PASS]
not_XX0
presented_VBN
._.
The_DT
loss_NN
attributable_JJ
to_PIN
shareholders_NN
dealt_VBN [WZPAST]
with_PIN
in_PIN
the_DT
accounts_NN
of_PIN
the_DT
Company_NN
is_VPRT [BEMA]
821,000_CD
2002_CD
:_:
146,000_CD
profit_NN
._.
25_CD
Financial_NN
instruments_NOMZ
The_DT
Group_NN
holds_VPRT [PRIV]
financial_JJ
instruments_NOMZ
to_TO
finance_VB
its_PIT
operations_NOMZ
and_CC
to_TO
manage_VB
the_DT
currency_NN
risk_NN
that_TSUB
arises_VPRT
from_PIN
these_DEMO
operations_NOMZ
._.
The_DT
Group_NN
finances_VPRT
its_PIT
operations_NOMZ
through_PIN
a_DT
combination_NOMZ
of_PIN
equity_NOMZ
,_,
convertible_JJ
bonds_NN
,_,
bank_NN
loans_NN
and_CC
other_JJ
borrowings_GER
._.
The_DT
main_JJ
risks_NN
arising_VBG [WZPRES]
from_PIN
the_DT
groups_NN
financial_JJ
instruments_NOMZ
are_VPRT
liquidity_NOMZ
risk_NN
,_,
foreign_JJ
currency_NN
risk_NN
,_,
interest_NN
rate_NN
risk_NN
and_PHC
credit_NN
risk_NN
._.
Liquidity_NOMZ
risk_NN
The_DT
Groups_NN
policy_NN
is_VPRT
to_TO
maintain_VB [PUBV]
continuity_NOMZ
of_PIN
funding_VBG
through_PIN
a_DT
mixture_NN
of_PIN
long-term_JJ
debt_NN
and_PHC
bank_NN
loans_NN
,_,
raised_VBD
to_TO
cover_VB
specific_JJ
projects_NN
,_,
and_ANDC
through_PIN
the_DT
issue_NN
of_PIN
shares_NN
to_PIN
collaborative_JJ
partners_NN
,_,
where_RB
necessary_JJ
,_,
to_TO
finance_VB
development_NOMZ
contracts_NN
._.
Short-term_JJ
flexibility_NOMZ
is_VPRT [PASS]
provided_VBN
through_PIN
the_DT
use_NN
of_PIN
overdrafts_NN
._.
The_DT
maturity_NOMZ
profile_NN
of_PIN
the_DT
Groups_NN
debt_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
at_PIN
note_NN
c._NN
Foreign_JJ
currency_NN
risk_NN
All_QUAN
of_PIN
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
based_VBN
overseas_PLACE
in_PIN
Continental_NN
Europe_NN
and_PHC
North_NN
America_NN
giving_VBG [WZPRES]
rise_NN
to_PIN
exposures_NN
to_PIN
changes_NN
in_PIN
foreign_JJ
exchange_NN
rates_NN
notably_RB
the_DT
Swiss_JJ
Franc_NN
,_,
Euro_NN
,_,
Swedish_NN
Krona_NN
,_,
US_FPP1
Dollar_NN
and_PHC
Canadian_NN
Dollar_NN
._.
To_TO
minimize_VB
the_DT
impact_NN
of_PIN
any_QUAN
fluctuations_NOMZ
,_,
the_DT
Groups_NN
policy_NN
has_VPRT [SPAU] [PEAS]
historically_RB
been_VBN
to_TO
maintain_VB [PUBV]
natural_JJ
hedges_NN
by_PIN
relating_VBG
the_DT
structure_NN
of_PIN
borrowings_GER
to_PIN
the_DT
trading_GER
cash_NN
flows_VPRT
that_DEMP
generate_VB
them_TPP3
._.
Where_RB
subsidiaries_NN
are_VPRT [PASS]
funded_VBN
centrally_RB
,_,
this_DEMP
is_VPRT [BYPA]
achieved_VBN
by_PIN
the_DT
use_NN
of_PIN
long-term_JJ
loans_NN
,_,
the_DT
exchange_NN
differences_NN
on_PIN
which_WDT [PIRE]
are_VPRT [PASS]
taken_VBN
to_PIN
reserves_NN
._.
Where_RB
it_PIT
has_VPRT [PEAS]
not_XX0
been_VBN [BEMA]
possible_PRED
to_TO
use_VB
natural_JJ
hedges_NN
,_,
currency_NN
options_NOMZ
,_,
accrual_NN
forward_RB
options_NOMZ
and_CC
forward_JJ
currency_NN
contracts_NN
are_VPRT [PASS]
used_VBN
._.
The_DT
Group_NN
has_VPRT [PEAS]
used_VBN
these_DEMO
financial_JJ
instruments_NOMZ
during_PIN
the_DT
year_NN
to_TO
minimize_VB
the_DT
currency_NN
exposure_NN
on_PIN
operational_JJ
transactions_NOMZ
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
76_CD
77_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
Interest_NN
rate_NN
risk_NN
The_DT
Group_NN
borrows_VPRT
at_PIN
fixed_VBN
and_PHC
floating_VBG
rates_NN
of_PIN
interest_NN
as_IN
deemed_VBN [PRIV]
appropriate_JJ
for_PIN
its_PIT
circumstances_NN
._.
Where_RB
necessary_JJ
the_DT
Group_NN
uses_VPRT
several_QUAN
interest_NN
rate_NN
swaps_NN
to_TO
achieve_VB
the_DT
desired_VBN [SUAV]
interest_NN
rate_NN
profile_NN
._.
During_PIN
the_DT
year_NN
the_DT
Group_NN
had_VBD
several_QUAN
cancellable_JJ
,_,
floating_VBG
rate_NN
,_,
interest_NN
rate_NN
swaps_NN
on_PIN
30_CD
million_CD
of_PIN
the_DT
6_CD
%_NN
convertible_JJ
bond_NN
liability_NOMZ
._.
The_DT
interest_NN
rate_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
notes_NN
a_DT
and_CC
b_NN
respectively_RB
._.
Credit_NN
risk_NN
The_NN
Group_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
credit_NN
related_VBN
losses_NN
in_PIN
the_DT
event_NN
of_PIN
non-performance_JJ
by_PIN
third_JJ
parties_NN
to_PIN
financial_JJ
instruments_NOMZ
._.
The_DT
Group_NN
does_VPRT
not_XX0
expect_VB [PRIV]
any_QUAN
third_JJ
parties_NN
to_TO
fail_VB
to_TO
meet_VB
their_TPP3
obligations_NOMZ
given_VBN
the_DT
policy_NN
of_PIN
selecting_VBG
only_DWNT
parties_NN
with_PIN
high_JJ
credit_NN
ratings_GER
and_CC
minimizing_VBG
its_PIT
exposure_NN
to_PIN
any_QUAN
one_CD
institution_NOMZ
._.
In_PIN
the_DT
numerical_JJ
disclosures_NN
that_TSUB
follow_VPRT
,_,
short-term_JJ
debtors_NN
and_PHC
creditors_NN
that_TSUB
arise_VPRT
directly_RB
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
Groups_NN
operations_NOMZ
are_VPRT [PASS]
excluded_VBN
from_PIN
all_QUAN
disclosures_NN
with_PIN
the_DT
exception_NOMZ
of_PIN
note_NN
f_SYM
on_PIN
currency_NN
exposures_NN
._.
a_DT
Interest_NN
rate_NN
and_PHC
currency_NN
profile_NN
of_PIN
financial_JJ
assets_NN
31_CD
December_NN
2003_CD
Weighted_JJ
average_JJ
Weighted_NN
Noninterest_NN
rate_NN
average_JJ
Floating_VBG
interest_NN
Fixed_VBN
rate_NN
on_PIN
fixed_JJ
time_NN
for_PIN
rate_NN
bearing_GER
Total_JJ
financial_JJ
financial_JJ
which_WDT
rate_NN
financial_JJ
financial_JJ
financial_JJ
assets_NN
assets_NN
is_VPRT [PASS]
fixed_VBN
assets_NN
assets_NN
assets_NN
Currency_NN
000_CD
%_NN
months_NN
000 000 000_CD
Sterling_GER
7,981_CD
4.94_CD
15.2_CD
6,016_CD
2,129_CD
16,126_CD
$_$
US_FPP1
568_CD
12.00_CD
59.5_CD
7,335_CD
18,728_CD
26,631_CD
Swiss_JJ
francs_NN
192_CD
2_CD
194_CD
$_$
Canadian_JJ
821_CD
629_CD
1,450_CD
Euro_NN
1,170_CD
64_CD
1,234_CD
Swedish_NN
Krona_NN
610_CD
610_CD
8,549_CD
5.41_CD
18.1_CD
16,144_CD
21,552_CD
46,245_CD
Total_JJ
financial_JJ
assets_NN
comprise_VPRT
fixed_VBN
asset_NN
investments_NOMZ
of_PIN
22.0_CD
million_CD
2002_CD
:_:
18.9_CD
million_CD
,_,
current_JJ
asset_NN
investments_NOMZ
of_PIN
1.0_CD
million_CD
2002_CD
:_:
2.0_CD
million_CD
and_CC
cash_NN
and_CC
short-term_JJ
bank_NN
deposits_NN
of_PIN
23.2_CD
million_CD
2002_CD
:_:
28.1_CD
million_CD
._.
Floating_VBG
rate_NN
financial_JJ
assets_NN
bear_VPRT
interest_NN
at_PIN
rates_NN
based_VBN [WZPAST]
upon_PIN
the_DT
floating_VBG
base_NN
rate_NN
in_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
funds_NN
are_VPRT [PASS]
held_VBN [PRIV]
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
31_CD
December_NN
2002_CD
Weighted_JJ
average_JJ
Weighted_NN
Noninterest_NN
rate_NN
average_JJ
Floating_VBG
interest_NN
Fixed_VBN
rate_NN
on_PIN
fixed_JJ
time_NN
for_PIN
rate_NN
bearing_GER
Total_JJ
financial_JJ
financial_JJ
which_WDT
rate_NN
financial_JJ
financial_JJ
financial_JJ
assets_NN
assets_NN
is_VPRT [PASS]
fixed_VBN
assets_NN
assets_NN
assets_NN
Currency_NN
000_CD
%_NN
months_NN
000 000 000_CD
Sterling_GER
1,961_CD
5.00_CD
54.0_CD
18,680_CD
36_CD
20,677_CD
$_$
US_FPP1
4,292_CD
16,663_CD
20,955_CD
Swiss_JJ
francs_NN
1,870_CD
1,870_CD
$_$
Canadian_JJ
2,026_CD
2,228_CD
4,254_CD
Euro_NN
617_CD
617_CD
Swedish_NN
Krona_NN
523_CD
523_CD
1,961_CD
5.00_CD
54.0_CD
28,008_CD
18,927_CD
48,896_CD
b_NN
Interest_NN
rate_NN
and_PHC
currency_NN
profile_NN
of_PIN
financial_JJ
liabilities_NOMZ
The_DT
interest_NN
rate_NN
risk_NN
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
after_IN
taking_VBG
into_PIN
account_NN
the_DT
interest_NN
rate_NN
and_PHC
currency_NN
swaps_NN
used_VBN
to_TO
manage_VB
the_DT
interest_NN
and_PHC
currency_NN
profile_NN
was_VBD
:_:
31_CD
December_NN
2003_CD
Weighted_JJ
average_JJ
Weighted_NN
Noninterest_NN
rate_NN
average_JJ
Floating_VBG
interest_NN
Weighted_NN
Fixed_NN
rate_NN
on_PIN
fixed_JJ
time_NN
for_PIN
rate_NN
bearing_GER
average_JJ
Total_JJ
financial_JJ
financial_JJ
which_WDT
rate_NN
financial_JJ
financial_JJ
time_NN
to_PIN
financial_JJ
liabilities_NOMZ
liabilities_NOMZ
is_VPRT [PASS]
fixed_VBN
liabilities_NOMZ
assets_NN
maturity_NOMZ
assets_NN
Currency_NN
000_CD
%_NN
months_NN
000_CD
000_CD
months_NN
000_CD
Sterling_GER
29,400_CD
6.00_CD
17.5_CD
30,000_CD
11,310_CD
28.0_CD
70,710_CD
$_$
US_FPP1
2,701_CD
7.99_CD
35.7_CD
559_CD
3,070_CD
136.0_CD
6,330_CD
Swiss_JJ
francs_NN
4,496_CD
3.66_CD
23.0_CD
5,940_CD
10,436_CD
$_$
Canadian_JJ
389_CD
120.0_CD
389_CD
Euro_NN
285_CD
405.0_CD
285_CD
Swedish_NN
Krona_NN
235_CD
6.38_CD
26.2_CD
235_CD
36,832_CD
5.86_CD
19.6_CD
36,499_CD
15,054_CD
59.6_CD
88,385_CD
Financial_NN
liabilities_NOMZ
comprise_VPRT
total_JJ
borrowings_GER
of_PIN
13.6_CD
million_CD
2002_CD
:_:
10.0_CD
million_CD
,_,
convertible_JJ
bonds_NN
of_PIN
59.4_CD
million_CD
2002_CD
:_:
59.4_CD
million_CD
,_,
non-equity_JJ
Deferred_NN
B_NN
Shares_NN
of_PIN
11.3_CD
million_CD
2002_CD
:_:
11.3_CD
million_CD
,_,
other_JJ
creditors_NN
of_PIN
3.8_CD
million_CD
2002_CD
:_:
4.6_CD
million_CD
and_CC
provisions_NN
of_PIN
0.3_CD
million_CD
2002_CD
:_:
0.2_CD
million_CD
._.
The_DT
effect_NN
of_PIN
the_DT
Groups_NN
interest_NN
rate_NN
swap_NN
is_VPRT
to_TO
classify_VB
30.0_CD
million_CD
of_PIN
the_DT
convertible_JJ
bond_NN
in_PIN
the_DT
above_PLACE
table_NN
as_IN
a_DT
floating_VBG
rate_NN
financial_JJ
liability_NOMZ
._.
Total_JJ
financial_JJ
liabilities_NOMZ
does_VPRT
not_XX0
agree_VB [SUAV] [PUBV]
to_PIN
the_DT
total_NN
of_PIN
the_DT
balance_NN
sheet_NN
captions_NOMZ
due_JJ
to_PIN
the_DT
presence_NN
of_PIN
609,000_CD
2002_CD
:_:
1,023,000_CD
of_PIN
unamortised_JJ
issue_NN
costs_NN
within_PIN
the_DT
value_NN
shown_VBN [PRIV] [WZPAST]
on_PIN
the_DT
balance_NN
sheet_NN
for_PIN
convertible_JJ
bonds_NN
._.
All_QUAN
floating_VBG
rate_NN
financial_JJ
liabilities_NOMZ
,_,
in_PIN
both_DT
2003_CD
and_CC
2002_CD
,_,
are_VPRT
interest_NN
bearing_GER
financial_JJ
liabilities_NOMZ
that_TSUB
bear_VPRT
interest_NN
at_PIN
interest_NN
rates_NN
based_VBN [WZPAST]
on_PIN
LIBOR_NN
,_,
prime_JJ
and_PHC
other_JJ
bank_NN
based_VBN
lending_GER
rates_NN
in_PIN
the_DT
country_NN
in_PIN
which_WDT [PIRE]
the_DT
liability_NOMZ
arises_VPRT
,_,
which_WDT [SERE]
are_VPRT [PASS]
fixed_VBN
for_PIN
periods_NN
of_PIN
up_RB
to_PIN
12_CD
months_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
78_CD
79_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
31_CD
December_NN
2002_CD
Weighted_JJ
average_JJ
Weighted_NN
Noninterest_NN
rate_NN
average_JJ
Floating_VBG
interest_NN
Weighted_NN
Fixed_NN
rate_NN
on_PIN
fixed_JJ
time_NN
for_PIN
rate_NN
bearing_GER
average_JJ
Total_JJ
financial_JJ
financial_JJ
which_WDT
rate_NN
financial_JJ
financial_JJ
time_NN
to_PIN
financial_JJ
liabilities_NOMZ
liabilities_NOMZ
is_VPRT [PASS]
fixed_VBN
liabilities_NOMZ
assets_NN
maturity_NOMZ
assets_NN
Currency_NN
000_CD
%_NN
months_NN
000_CD
000_CD
months_NN
000_CD
Sterling_GER
29,400_CD
6.00_CD
29.5_CD
30,000_CD
11,310_CD
40.0_CD
70,710_CD
$_$
US_FPP1
25_CD
5.25_CD
40.0_CD
621_CD
3,269_CD
144.0_CD
3,915_CD
Swiss_JJ
francs_NN
4,560_CD
3.64_CD
13.5_CD
4,897_CD
9,457_CD
Euro_NN
863_CD
6.25_CD
11.0_CD
201_CD
417.0_CD
1,064_CD
Swedish_NN
Krona_NN
319_CD
7.25_CD
27.8_CD
319_CD
35,167_CD
5.71_CD
27.0_CD
35,518_CD
14,780_CD
68.1_CD
85,465_CD
c_NN
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Within_PIN
one_CD
year_NN
4,530_CD
2,927_CD
Between_PIN
one_CD
and_CC
two_CD
years_NN
60,662_CD
5,256_CD
Between_PIN
two_CD
and_CC
five_CD
years_NN
13,261_CD
71,587_CD
Beyond_NN
five_CD
years_NN
9,932_CD
5,695_CD
88,385_CD
85,465_CD
d_SYM
Borrowing_VBG
facilities_NOMZ
As_IN
at_PIN
31_CD
December_NN
2003_CD
the_DT
Group_NN
had_VBD
the_DT
following_VBG
undrawn_JJ
committed_JJ
borrowing_GER
facilities_NOMZ
available_JJ
._.
31_CD
December_NN
2003_CD
31_CD
December_NN
2002 000 000_CD
Expiring_VBG
within_PIN
one_CD
year_NN
158_CD
1,646_CD
e_SYM
Fair_NN
values_VPRT
The_DT
comparison_NN
of_PIN
fair_JJ
and_CC
book_NN
values_NN
of_PIN
all_QUAN
the_DT
Groups_NN
financial_JJ
instruments_NOMZ
as_IN
at_PIN
31_CD
December_NN
2003_CD
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Market_NN
value_NN
,_,
or_CC
Directors_NN
valuation_NOMZ
if_COND
a_DT
market_NN
value_NN
is_VPRT [BEMA]
unavailable_PRED
,_,
have_VPRT [PEAS]
been_VBN [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
fixed_VBN
and_CC
current_JJ
asset_NN
investments_NOMZ
._.
Market_NN
values_NN
have_VPRT [PEAS]
been_VBN [PASS]
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
fair_JJ
values_NN
of_PIN
all_QUAN
swaps_NN
and_CC
foreign_JJ
currency_NN
contracts_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
the_DT
non-equity_JJ
Deferred_NN
B_NN
Shares_NN
has_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
reference_NN
to_PIN
the_DT
Ordinary_NN
Share_NN
price_NN
at_PIN
31_CD
December_NN
2003_CD
,_,
based_VBN [PASTP]
upon_PIN
the_DT
Directors_NN
opinion_NN
that_TOBJ
12_CD
million_CD
Ordinary_NN
Shares_NN
will_PRMD
be_VB [PASS]
issued_VBN
in_PIN
settlement_NOMZ
of_PIN
the_DT
deferred_JJ
consideration_NOMZ
payable_JJ
on_PIN
the_DT
acquisition_NOMZ
of_PIN
Jago_NN
._.
See_VB [PRIV]
note_NN
22_CD
:_:
Share_NN
capital_NN
,_,
for_PIN
details_NN
of_PIN
the_DT
contingencies_NN
that_TSUB
shall_PRMD
determine_VB [SUAV] [PRIV]
the_DT
issuance_NN
of_PIN
the_DT
Ordinary_NN
Shares_NN
._.
The_DT
fair_JJ
values_NN
of_PIN
all_QUAN
other_JJ
items_NN
have_VPRT [PEAS]
been_VBN [BYPA]
calculated_VBN [PRIV]
by_PIN
discounting_VBG
future_JJ
cash_NN
flows_VPRT
at_PIN
interest_NN
rates_NN
prevailing_VBG [WZPRES]
at_PIN
31_CD
December_NN
2003_CD
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
Book_NN
values_NN
Fair_NN
values_VPRT
31_CD
December_NN
2003 000 000_CD
Financial_NN
instruments_NOMZ
held_VBD [PRIV]
or_CC
issued_VBD
to_TO
finance_VB
the_DT
Groups_NN
operations_NOMZ
Fixed_VBN
asset_NN
investments_NOMZ
22,024_CD
28,745_CD
Current_JJ
asset_NN
investments_NOMZ
981_CD
981_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
3,052_CD
3,052_CD
Short-term_JJ
bank_NN
deposits_NN
20,188_CD
20,188_CD
Short-term_JJ
borrowings_GER
and_CC
current_JJ
portion_NOMZ
of_PIN
long-term_JJ
borrowings_GER
4,530_CD
4,530_CD
Long-term_JJ
convertible_JJ
debt_NN
59,400_CD
56,218_CD
Other_JJ
long-term_JJ
debt_NN
13,145_CD
13,145_CD
Non-equity_NOMZ
Deferred_VBN
B_NN
Shares_NN
11,310_CD
9,030_CD
42,140_CD
29,957_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
to_TO
manage_VB
the_DT
Groups_NN
currency_NN
profile_NN
Interest_NN
rate_NN
swaps_NN
322_CD
Canadian_JJ
$_$
currency_NN
options_NOMZ
Euro_NN
currency_NN
options_NOMZ
21_CD
Swiss_JJ
franc_NN
currency_NN
options_NOMZ
12_CD
Swedish_JJ
Krona_NN
currency_NN
options_NOMZ
59_CD
Forward_RB
currency_NN
contracts_NN
18_CD
354_CD
Book_NN
values_NN
Fair_NN
values_VPRT
31_CD
December_NN
2002 000 000_CD
Financial_NN
instruments_NOMZ
held_VBD [PRIV]
or_CC
issued_VBD
to_TO
finance_VB
the_DT
Groups_NN
operations_NOMZ
Fixed_VBN
asset_NN
investments_NOMZ
18,874_CD
17,287_CD
Current_JJ
asset_NN
investments_NOMZ
1,961_CD
1,961_CD
Cash_NN
at_PIN
bank_NN
and_CC
in_PIN
hand_NN
7,394_CD
7,394_CD
Short-term_JJ
bank_NN
deposits_NN
20,667_CD
20,667_CD
Short-term_JJ
borrowings_GER
and_CC
current_JJ
portion_NOMZ
of_PIN
long-term_JJ
borrowings_GER
2,927_CD
2,927_CD
Long-term_JJ
convertible_JJ
debt_NN
59,400_CD
53,863_CD
Other_JJ
long-term_JJ
debt_NN
11,828_CD
11,707_CD
Non-equity_NOMZ
Deferred_VBN
B_NN
Shares_NN
11,310_CD
4,980_CD
36,569_CD
26,168_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
to_TO
manage_VB
the_DT
Groups_NN
currency_NN
profile_NN
Interest_NN
rate_NN
swaps_NN
452_CD
Euro_NN
currency_NN
options_NOMZ
85_CD
US$_$
currency_NN
options_NOMZ
13_CD
Forward_RB
currency_NN
contracts_NN
146_CD
500_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
80_CD
81_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
f_SYM
Currency_NN
exposures_NN
The_DT
following_JJ
analysis_NN
shows_VPRT [PRIV]
the_DT
net_JJ
monetary_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
Group_NN
companies_NN
that_TSUB
are_VPRT [PASS]
not_XX0
denominated_VBN
in_PIN
their_TPP3
functional_JJ
currency_NN
and_ANDC
therefore_CONJ
give_VB
rise_VB
to_TO
exchange_VB
gains_NN
and_PHC
losses_NN
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
both_DT
2003_CD
and_CC
2002_CD
._.
31_CD
December_NN
2003_CD
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
liabilities_NOMZ
Swedish_JJ
Swiss_JJ
$_$
Krona_NN
Sterling_GER
$_$
US_FPP1
Euro_NN
francs_NN
Canadian_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Operating_VBG
Company_NN
000 000 000 000_CD
000 000 000_CD
Sterling_GER
3,796_CD
847_CD
6_CD
4,649_CD
$_$
US_FPP1
3,579_CD
65_CD
3,644_CD
Euro_NN
245_CD
17_CD
2,622_CD
2,850_CD
Swiss_JJ
francs_NN
5_CD
10,280_CD
2,419_CD
220_CD
12,474_CD
$_$
Canadian_JJ
1,038_CD
1,391_CD
71_CD
424_CD
Swedish_NN
Krona_NN
2,568_CD
54_CD
2,622_CD
5_CD
5,416_CD
4,753_CD
491_CD
2,622_CD
6_CD
13,283_CD
31_CD
December_NN
2002_CD
Net_JJ
foreign_JJ
currency_NN
monetary_JJ
assets_NN
liabilities_NOMZ
Swiss_JJ
$_$
Sterling_GER
$_$
US_FPP1
Euro_NN
francs_NN
Canadian_JJ
Total_NN
Functional_NN
currency_NN
of_PIN
Operating_VBG
Company_NN
000 000 000 000_CD
000_CD
000_CD
Sterling_GER
2,232_CD
617_CD
1_CD
2,850_CD
$_$
US_FPP1
15,956_CD
9_CD
34_CD
15,999_CD
Euro_NN
2,025_CD
96_CD
2,225_CD
296_CD
Swiss_JJ
francs_NN
928_CD
3,142_CD
528_CD
582_CD
1,104_CD
$_$
Canadian_JJ
1,904_CD
400 130 550_CD
2,724_CD
Swedish_NN
Krona_NN
1,343_CD
1,343_CD
18,348_CD
5,870_CD
50_CD
2,775_CD
615_CD
10,368_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
25_CD
Financial_NN
instruments_NOMZ
continued_VBD
g_JJ
Hedging_GER
As_IN
explained_VBN [PUBV]
above_PLACE
,_,
the_DT
Groups_NN
policy_NN
is_VPRT
to_TO
hedge_VB
interest_NN
rate_NN
exposures_NN
through_PIN
the_DT
use_NN
of_PIN
interest_NN
rate_NN
swaps_NN
and_PHC
currency_NN
exposures_NN
through_PIN
the_DT
use_NN
of_PIN
currency_NN
options_NOMZ
,_,
accrual_NN
forward_RB
options_NOMZ
and_CC
forward_JJ
currency_NN
contracts_NN
._.
The_DT
table_NN
below_PLACE
shows_NN
the_DT
extent_NN
to_PIN
which_WDT [PIRE]
the_DT
Group_NN
has_VPRT
off-balance_JJ
sheet_NN
unrecognised_JJ
and_PHC
on-balance_JJ
sheet_NN
deferred_VBN
gains_NN
and_PHC
losses_NN
in_PIN
respect_NN
of_PIN
hedges_NN
at_PIN
the_DT
beginning_GER
and_PHC
end_NN
of_PIN
the_DT
year_NN
:_:
31_CD
December_NN
2003_CD
Unrecognised_NN
Deferred_NN
Gains_NN
Losses_NN
Net_JJ
total_NN
Gains_NN
Losses_NN
Net_JJ
total_NN
000 000 000 000_CD
000_CD
000_CD
Gains_NN
losses_NN
on_PIN
hedges_NN
at_PIN
1_CD
January_NN
2003_CD
598_CD
98_CD
500_CD
Changes_NN
in_PIN
value_NN
from_PIN
1_CD
January_NN
2003_CD
to_PIN
settlement_NOMZ
6_CD
85_CD
91_CD
Gains_NN
losses_NN
arising_VBG [WZPRES]
in_PIN
previous_JJ
years_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
2003_CD
152_CD
13_CD
139_CD
Gains_NN
losses_NN
not_XX0
recognized_VBN [PRIV]
in_PIN
2003_CD
arising_VBG
before_IN
1_CD
January_NN
2003 452 452_CD
Arising_VBG
in_PIN
2003_CD
59_CD
39_CD
98_CD
Gains_NN
losses_NN
on_PIN
hedges_NN
at_PIN
31_CD
December_NN
2003_CD
393_CD
39_CD
354_CD
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Company_NN
had_VBD
European_JJ
style_NN
accrual_NN
forward_RB
options_NOMZ
to_TO
purchase_VB
142,000_CD
of_PIN
Sterling_GER
each_QUAN
week_NN
for_PIN
the_DT
4_CD
weeks_NN
ending_VBG [WZPRES]
in_PIN
January_NN
2004_CD
,_,
22,000_CD
of_PIN
Euro_NN
each_QUAN
week_NN
for_PIN
the_DT
8_CD
weeks_NN
ending_VBG [WZPRES]
in_PIN
February_NN
2004_CD
and_CC
123,000_CD
of_PIN
Swiss_JJ
Francs_NN
each_QUAN
week_NN
for_PIN
the_DT
36_CD
weeks_NN
ending_VBG [WZPRES]
in_PIN
September_NN
2004_CD
._.
In_CONJ
addition_NULL
,_,
the_DT
Company_NN
had_VBD
a_DT
cylinder_NN
structure_NN
containing_VBG [WZPRES]
knock_VB
ins_NN
to_TO
purchase_VB
0.5_CD
million_CD
of_PIN
Swedish_JJ
Krona_NN
each_QUAN
month_NN
for_PIN
the_DT
6_CD
months_NN
ending_VBG [WZPRES]
in_PIN
June_NN
2004_CD
._.
At_PIN
31_CD
December_NN
2003_CD
,_,
the_DT
Company_NN
had_VBD
forward_JJ
currency_NN
contracts_NN
to_TO
purchase_VB
4.6_CD
million_CD
of_PIN
Euro_NN
,_,
2.3_CD
million_CD
of_PIN
US_FPP1
dollars_NN
,_,
0.3_CD
million_CD
of_PIN
Swedish_JJ
Krona_NN
and_CC
to_TO
sell_VB
0.3_CD
million_CD
of_PIN
Swiss_JJ
Francs_NN
._.
The_DT
excess_NN
of_PIN
fair_JJ
values_NN
over_IN
book_NN
values_NN
for_PIN
currency_NN
options_NOMZ
shown_VBN [PRIV] [WZPAST]
in_PIN
note_NN
25_CD
e_SYM
represents_VPRT
the_DT
unrecognised_JJ
hedging_GER
gain_NN
on_PIN
these_DEMO
instruments_NOMZ
as_IN
at_PIN
31_CD
December_NN
2003_CD
._.
The_DT
actual_JJ
gains_NN
or_CC
losses_NN
arising_VBG [WZPRES]
on_PIN
these_DEMO
currency_NN
options_NOMZ
will_PRMD
be_VB [BEMA]
dependent_PRED
on_PIN
future_JJ
exchange_NN
rates_NN
and_CC
will_PRMD
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
,_,
in_PIN
2004_CD
,_,
as_IN
the_DT
operational_JJ
transactions_NOMZ
to_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
linked_VBN
occur_VPRT
._.
Unrecognised_JJ
gains_NN
at_PIN
31_CD
December_NN
2003_CD
include_VPRT
0.3_CD
million_CD
in_PIN
relation_NOMZ
to_PIN
the_DT
cancellable_JJ
swap_NN
agreement_NOMZ
._.
This_DEMP
is_VPRT [PASS]
based_VBN
upon_PIN
the_DT
swap_NN
agreement_NOMZ
continuing_VBG [WZPRES]
for_PIN
the_DT
life_NN
of_PIN
the_DT
convertible_JJ
bond_NN
._.
The_DT
Royal_NN
Bank_NN
of_PIN
Scotland_NN
last_JJ
exercised_VBN
its_PIT
right_NN
to_TO
cancel_VB
and_PHC
replace_VB
the_DT
swap_NN
in_PIN
November_NN
2002_CD
,_,
and_ANDC
it_PIT
has_VPRT [PEAS]
remained_VBN
in_PIN
place_NN
since_OSUB
._.
31_CD
December_NN
2002_CD
Unrecognised_NN
Deferred_NN
Gains_NN
Losses_NN
Net_JJ
total_NN
Gains_NN
Losses_NN
Net_JJ
total_NN
000 000 000 000_CD
000_CD
000_CD
Gains_NN
losses_NN
on_PIN
hedges_NN
at_PIN
1_CD
January_NN
2002_CD
31_CD
31_CD
20_CD
20_CD
Changes_NN
in_PIN
value_NN
from_PIN
1_CD
January_NN
2002_CD
to_PIN
settlement_NOMZ
262_CD
262_CD
Gains_NN
losses_NN
arising_VBG [WZPRES]
in_PIN
2001_CD
recognized_VBN [PRIV]
in_PIN
2002 231 231_CD
20_CD
20_CD
Gains_NN
losses_NN
not_XX0
recognized_VBN [PRIV]
in_PIN
2002_CD
arising_VBG
before_IN
1_CD
January_NN
2002_CD
Arising_VBG
in_PIN
2002_CD
598_CD
98_CD
500_CD
Gains_NN
losses_NN
on_PIN
hedges_NN
at_PIN
31_CD
December_NN
2002_CD
598_CD
98_CD
500_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
82_CD
83_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
26_CD
Pension_NN
arrangements_NOMZ
The_DT
Group_NN
operates_VPRT
various_JJ
defined_VBN
contribution_NOMZ
plans_NN
for_PIN
its_PIT
employees_NN
in_PIN
the_DT
UK_NN
,_,
Switzerland_NN
,_,
US_FPP1
,_,
Sweden_NN
and_PHC
Canada_NN
._.
The_DT
Groups_NN
contributions_NOMZ
to_PIN
these_DEMO
plans_NN
are_VPRT [PASS]
charged_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
the_DT
period_NN
to_PIN
which_WDT [PIRE]
they_TPP3
relate_VPRT
,_,
and_ANDC
the_DT
assets_NN
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
separate_JJ
trustee_NN
administered_VBN
funds_NN
._.
The_DT
Group_NN
operates_VPRT
an_DT
unfunded_JJ
defined_VBN
benefit_NN
scheme_NN
in_PIN
respect_NN
of_PIN
its_PIT
employees_NN
in_PIN
France_NN
based_VBN [WZPAST]
on_PIN
the_DT
national_JJ
collective_JJ
agreement_NOMZ
of_PIN
the_DT
pharmaceutical_JJ
industry_NN
,_,
and_ANDC
a_DT
provision_NN
of_PIN
285,000_CD
is_VPRT [PASS]
included_VBN
in_PIN
note_NN
18_CD
:_:
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
in_PIN
respect_NN
of_PIN
these_DEMO
obligations_NOMZ
._.
Under_IN
the_DT
transitional_JJ
provisions_NN
of_PIN
FRS17_NN
:_:
Retirement_NOMZ
Benefits_NN
certain_JJ
disclosures_NN
for_PIN
the_DT
defined_VBN
benefit_NN
scheme_NN
in_PIN
France_NN
are_VPRT [PASS]
required_VBN [SUAV]
as_IN
follows_VPRT
:_:
As_IN
at_PIN
December_NN
2003_CD
a_DT
valuation_NOMZ
was_VBD [BYPA]
performed_VBN
by_PIN
professionally_RB
qualified_VBN
actuaries_NN
,_,
Socit_NN
fide_NN
Prospective_JJ
Actuariat_NN
et_NN
Conseil_NN
,_,
on_PIN
the_DT
present_JJ
value_NN
of_PIN
the_DT
accrued_VBN
liabilities_NOMZ
calculated_VBN [PRIV]
under_IN
the_DT
projected_VBN
unit_NN
method_NN
._.
The_DT
principal_JJ
assumptions_NOMZ
made_VBN [WZPAST]
by_PIN
the_DT
actuaries_NN
were_VBD
:_:
2003 2002 2001_CD
%_NN
per_PIN
%_NN
per_PIN
%_NN
per_PIN
annum_NN
annum_NN
annum_NN
Inflation_NOMZ
rate_NN
1.75_CD
1.75_CD
2.0_CD
Rate_NN
of_PIN
increase_NN
in_PIN
salaries_NN
2.75_CD
2.75_CD
3.0_CD
Discount_NN
rate_NN
5.25_CD
5.25_CD
5.5_CD
Analysis_NN
of_PIN
amounts_NN
charged_VBN [WZPAST]
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
in_PIN
respect_NN
of_PIN
the_DT
defined_VBN
benefit_NN
scheme_NN
under_IN
FRS_NN
17 2003 2002 000_CD
000_CD
Current_JJ
service_NN
cost_NN
18_CD
24_CD
Past_JJ
service_NN
cost_NN
Interest_NN
on_PIN
pension_NN
scheme_NN
liabilities_NOMZ
22_CD
21_CD
Total_JJ
charge_NN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
40_CD
45_CD
Movement_NOMZ
in_PIN
deficit_NN
during_PIN
the_DT
year_NN
2003 2002 000 000_CD
Opening_GER
deficit_NN
382_CD
382_CD
Exchange_NN
adjustment_NOMZ
31_CD
25_CD
Current_JJ
service_NN
charge_NN
40_CD
45_CD
Benefit_NN
payments_NOMZ
made_VBD
9_CD
Unrecognised_JJ
past_JJ
service_NN
cost_NN
183_CD
Actuarial_NN
gain_NN
recognized_VBD [PRIV]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
33_CD
61_CD
Closing_GER
deficit_NN
603_CD
382_CD
SkyePharma_NN
annual_JJ
report_NN
2003_CD
26_CD
Pension_NN
arrangements_NOMZ
continued_VBD
Amounts_NN
recorded_VBN [WZPAST]
in_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
under_IN
FRS17_NN
2003_CD
2002_CD
Experience_NN
gains_NN
arising_VBG [WZPRES]
on_PIN
scheme_NN
liabilities_NOMZ
000_CD
24_CD
17_CD
Percentage_NN
of_PIN
scheme_NN
liabilities_NOMZ
%_NN
6_CD
4_CD
Changes_NN
in_PIN
assumption_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
present_JJ
value_NN
of_PIN
scheme_NN
liabilities_NOMZ
000_CD
9_CD
44_CD
Percentage_NN
of_PIN
scheme_NN
liabilities_NOMZ
%_NN
2_CD
12_CD
Total_JJ
actuarial_JJ
gain_NN
000_CD
33_CD
61_CD
Percentage_NN
of_PIN
scheme_NN
liabilities_NOMZ
%_NN
16_CD
16_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
under_IN
FRS17_NN
2003 2002 000 000_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
per_PIN
balance_NN
sheet_NN
305,375_CD
264,006_CD
Pension_NN
liability_NOMZ
under_IN
FRS_NN
17 603 382_CD
Pension_NN
liability_NOMZ
under_IN
SSAP_NN
24_CD
:_:
Accounting_GER
for_PIN
pension_NN
costs_NN
285_CD
201_CD
Profit_NN
and_PHC
loss_NN
reserve_NN
under_IN
FRS_NN
17_CD
305,693_CD
264,187_CD
Net_JJ
assets_NN
under_IN
FRS_NN
17 2003 2002 000_CD
000_CD
Net_JJ
assets_NN
per_PIN
balance_NN
sheet_NN
86,265_CD
124,270_CD
Pension_NN
liability_NOMZ
under_IN
FRS_NN
17 603 382_CD
Pension_NN
liability_NOMZ
under_IN
SSAP_NN
24 285 201_CD
Net_JJ
assets_NN
under_IN
FRS_NN
17_CD
85,947_CD
124,089_CD
27_CD
Related_VBN
party_NN
transactions_NOMZ
At_PIN
the_DT
end_NN
of_PIN
December_NN
1998_CD
,_,
Ian_NN
Gowrie-Smith_NN
through_PIN
a_DT
family-owned_JJ
trust_NN
acquired_VBD
a_DT
50_CD
%_NN
interest_NN
in_PIN
10_CD
East_NN
63rd_NN
Street_NN
Inc._NN
the_DT
company_NN
which_WDT [WHSUB]
owns_VPRT
10_CD
East_NN
63rd_NN
Street_NN
,_,
a_DT
property_NN
in_PIN
New_NN
York_NN
._.
In_PIN
December_NN
2002_CD
Mr._NN
Gowrie-Smith_NN
acquired_VBD
the_DT
remaining_VBG
50_CD
%_NN
interest_NN
._.
SkyePharma_NN
PLC_NN
has_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
occupation_NOMZ
of_PIN
that_DEMO
property_NN
since_OSUB
January_NN
1997_CD
,_,
subject_JJ
to_PIN
tenancy_NN
agreements_NOMZ
based_VBN [WZPAST]
upon_PIN
independent_JJ
valuation_NOMZ
._.
In_PIN
August_NN
2003_CD
the_DT
company_NN
took_VBD
occupation_NOMZ
of_PIN
the_DT
entire_JJ
building_GER
under_IN
an_DT
eight-year_JJ
tenancy_NN
agreement_NOMZ
,_,
at_PIN
which_WDT [PIRE]
time_NN
the_DT
annual_JJ
rent_NN
was_VBD [PASS]
increased_VBN
from_PIN
$_$
420,000_CD
per_PIN
annum_NN
to_TO
$_$
720,000_CD
per_PIN
annum_NN
until_IN
August_NN
2008_CD
,_,
and_ANDC
$_$
942,500_CD
per_PIN
annum_NN
from_PIN
August_NN
2008_CD
to_PIN
August_NN
2011_CD
._.
28_CD
Acquisition_NOMZ
of_PIN
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
On_PIN
13_CD
May_POMD
2002_CD
SkyePharma_NN
acquired_VBD
the_DT
entire_JJ
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
,_,
of_PIN
Sweden_NN
,_,
for_PIN
3.6_CD
million_CD
in_PIN
cash_NN
including_VBG [WZPRES]
acquisition_NOMZ
costs_NN
and_CC
the_DT
assumption_NOMZ
of_PIN
0.4_CD
million_CD
of_PIN
net_JJ
liabilities_NOMZ
._.
The_DT
acquired_VBN
rights_NN
include_VPRT
Bioglans_NN
Biosphere_NN
injectable_JJ
technology_NN
and_CC
those_DEMO
rights_NN
to_PIN
DermaStick_NN
,_,
Crystalip_NN
and_PHC
ES-Gel_NN
topical_JJ
drug_NN
delivery_NN
technologies_NN
that_TSUB
remained_VBD
with_PIN
Bioglan_NN
after_IN
the_DT
January_NN
2001_CD
development_NOMZ
and_PHC
commercialisation_NOMZ
licensing_GER
agreement_NOMZ
._.
The_DT
acquisition_NOMZ
method_NN
was_VBD [PASS]
adopted_VBN
and_CC
goodwill_NN
of_PIN
4.0_CD
million_CD
arose_VBD
on_PIN
the_DT
acquisition_NOMZ
._.
By_PIN
consideration_NOMZ
of_PIN
the_DT
likely_JJ
commercial_JJ
life_NN
of_PIN
the_DT
technology_NN
acquired_VBN
,_,
the_DT
Directors_NN
determined_VBD [SUAV] [PRIV]
that_THVC
a_DT
suitable_JJ
period_NN
over_IN
which_WDT
to_TO
amortise_VB
the_DT
goodwill_NN
was_VBD [BEMA]
20_CD
years_NN
._.
SkyePharma_NN
annual_JJ
report_NN
2003_CD
84_CD
85_CD
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
continued_VBD
28_CD
Acquisition_NOMZ
of_PIN
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
continued_VBD
Book_NN
values_NN
and_CC
fair_JJ
values_NN
000_CD
Fixed_JJ
assets_NN
Tangible_JJ
assets_NN
676_CD
Current_JJ
assets_NN
Debtors_NN
44_CD
Creditors_NN
amounts_VPRT
falling_VBG
due_JJ
within_PIN
one_CD
year_NN
1,095_CD
Net_JJ
current_JJ
liabilities_NOMZ
1,051_CD
Net_JJ
liabilities_NOMZ
375_CD
Satisfied_VBN
by_PIN
:_:
Cash_NN
3,500_CD
Expenses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
transaction_NOMZ
95_CD
Consideration_NOMZ
3,595_CD
Goodwill_NN
3,970_CD
Results_NN
of_PIN
the_DT
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
The_NN
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
prior_RB
to_PIN
the_DT
acquisition_NOMZ
formed_VBD
part_NN
of_PIN
Bioglan_NN
AB_NN
and_CC
did_VBD
not_XX0
report_VB [PUBV]
as_IN
a_DT
separate_JJ
unit_NN
._.
During_PIN
the_DT
period_NN
13_CD
May_POMD
2002_CD
to_PIN
31_CD
December_NN
2002_CD
the_DT
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
contributed_VBD
0.5_CD
million_CD
to_PIN
turnover_NN
,_,
a_DT
loss_NN
of_PIN
1.5_CD
million_CD
to_TO
operating_VBG
profit_NN
and_CC
a_DT
cash_NN
outflow_NN
of_PIN
1.3_CD
million_CD
to_PIN
net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
._.
29_CD
Subsequent_JJ
events_NN
In_PIN
April_NN
2004_CD
the_DT
Group_NN
issued_VBD
20_CD
million_CD
6_CD
%_NN
convertible_JJ
bonds_NN
,_,
with_PIN
a_DT
first_RB
put_VBN
after_IN
five_CD
years_NN
by_PIN
the_DT
holder_NN
of_PIN
the_DT
bonds_NN
,_,
and_ANDC
a_DT
final_JJ
maturity_NOMZ
of_PIN
May_POMD
2024_CD
._.
The_DT
bonds_NN
are_VPRT [BEMA]
convertible_PRED
at_PIN
the_DT
option_NOMZ
of_PIN
the_DT
holder_NN
into_PIN
SkyePharma_NN
Ordinary_NN
Shares_NN
at_PIN
a_DT
conversion_NN
price_NN
of_PIN
1.00_CD
at_PIN
any_QUAN
time_NN
prior_RB
to_PIN
maturity_NOMZ
._.
Unless_COND
previously_TIME
redeemed_VBN
or_CC
converted_VBN
,_,
the_DT
bonds_NN
will_PRMD
be_VB [BYPA]
redeemed_VBN
by_PIN
the_DT
Group_NN
at_PIN
their_TPP3
principal_JJ
amount_NN
in_PIN
May_POMD
2024_CD
._.
The_DT
convertible_JJ
bonds_NN
existing_VBG [WZPRES]
at_PIN
31_CD
December_NN
2003_CD
,_,
due_RB
in_PIN
June_NN
2005_CD
,_,
are_VPRT [BYPA]
not_XX0
affected_VBN
by_PIN
this_DEMO
transaction_NOMZ
._.
30_CD
Principal_NN
subsidiary_NN
undertakings_GER
%_NN
held_VBN [PRIV] [WZPAST]
of_PIN
nominal_JJ
Company_NN
Country_NN
of_PIN
incorporation_NOMZ
value_NN
and_PHC
voting_NN
rights_NN
Principal_NN
activities_NOMZ
SkyePharma_NN
Canada_NN
Inc._NN
._.
Canada_NN
100_CD
%_NN
Research_NN
and_PHC
development_NOMZ
SkyePharma_NN
Production_NOMZ
SAS_NN
France_NN
100_CD
%_NN
Manufacturing_GER
of_PIN
pharmaceuticals_NN
Krypton_NN
Limited_NN
Gibraltar_NN
100_CD
%_NN
Exploitation_NOMZ
of_PIN
intellectual_JJ
property_NN
SkyePharma_NN
AB_NN
Sweden_NN
100_CD
%_NN
Research_NN
and_PHC
development_NOMZ
Jago_NN
Holding_GER
AG_NN
Switzerland_NN
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
company_NN
Jagotec_NN
AG_NN
Switzerland_NN
100_CD
%_NN
Exploitation_NOMZ
of_PIN
intellectual_JJ
property_NN
SkyePharma_NN
AG_NN
Switzerland_NN
100_CD
%_NN
Research_NN
and_PHC
development_NOMZ
SkyePharma_NN
Holding_GER
AG_NN
Switzerland_NN
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
company_NN
SkyePharma_NN
Holding_GER
Inc._NN
._.
US_FPP1
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
company_NN
SkyePharma_NN
Inc._NN
._.
US_FPP1
100_CD
%_NN
Development_NOMZ
of_PIN
pharmaceuticals_NN
SkyePharma_NN
US_FPP1
Inc._NN
._.
US_FPP1
100_CD
%_NN
Development_NOMZ
of_PIN
pharmaceuticals_NN
and_PHC
licensing_GER
Directly_RB
held_VBN [PRIV]
by_PIN
the_DT
Company_NN
._.
Full_JJ
details_NN
of_PIN
all_QUAN
subsidiary_NN
undertakings_GER
will_PRMD
be_VB [PASS]
attached_VBN
to_PIN
the_DT
Companys_NN
Annual_JJ
Return_NN
to_TO
be_VB [PASS]
filed_VBN
with_PIN
the_DT
Registrar_NN
of_PIN
Companies_NN
._.
